5-fluorine-1h-pyrazolopyridines substituted and their use

专利摘要:
  5-FLUOR-1H-PIRAZOLOPYRIDINES SUBSTITUTED AND THEIR USE.The present patent application relates to new substituted 5-fluorine-1H-pyrazolopyridines, processes for their preparation, their use alone or in combinations for the treatment and / or prophylaxis of diseases, as well as their use for drug preparation for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of cardiovascular disorders.
公开号:BR112012030010A2
申请号:R112012030010-5
申请日:2011-05-24
公开日:2020-09-01
发明作者:Markus Follmann；Volkhart Min-Jian Li；Elke Hartmann；Joachim Mittendorf；Karl-Heinz Schelemmer；Rolf Jautelat；Donald Bierer；Johannes-Peter Stasch；Gorden Redlich；Jens Ackerstaff；Nils Griebenow；Walter Kroh；Andreas Knorr；Eva-Maria Becker；Frank Wunder
申请人:Bayer Intellectual Property Gmbh；
IPC主号:

专利说明:

Patent Specification Report for "5-FLUOR-1H-SUBSTITUTED PRAZOLOPYRIDINES AND THEIR USE". The present patent application concerns new substituted 5-fluorine-1H-pyrazolopyridines, processes for their preparation, their use 5 individually or in combinations for treatment and / or prophylaxis of diseases, as well as their use for preparation of drugs for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or prophylaxis of cardiovascular diseases. One of the most important cell transmission systems in 10 mammalian cells is cyclic guanosine monophosphate (CGMP). together with nitrogen monoxide (NO), which is released from the endothelium and transmits hormonal and mechanical signals, it forms the NO / CGMP system. The cyclan- guanylate. These catalyze the biosynthesis of CGMP of guanosine triphosphate (GTP). The
Ü. known representatives of this family can be divided into two groups, either according to structural characteristics or according to the type of ligands: the guanylate cyclases particulates simulable by natriuetic peptides, and the guanylate cyclones soluble, which can be stimulated soluble guanylate cyclases consist of two subunits, and most likely contain a heme per heterodimer, which is part of the regulatory center, which is of central importance to the activation mechanism. iron atom of the heme, and thus the activity of the enzyme is visibly increased. Free heme preparations, on the other hand, cannot be stimulated by NO. Carbon monoxide (CO) is also capable of binding to the iron atom heme central, but stimulation by 25 CO is noticeably less than that by NO. Through the formation of cGMP and the resulting regulation of phosphodiesterases, ion channels and protein kinases, guanylate cycl ase plays an important role in various physiological processes, particularly in the relaxation and proliferation of smooth muscle cells, in aggregation of platelets and platelet adhesion, and in the transmission of neural signals, as well as in diseases that are based on a disturbance of the processes mentioned above. Under pathophysiological conditions, the system
NO / CGMP can be suppressed, which for example, can elevate high blood pressure, platelet activation, increased cell proliferation, endothelial dysfunction, atherosclerosis, angina pectoris, heart failure, myocardial infarction, thrombosis, stroke and sexual dysfunction.
5 Due to the expected high efficacy and few side effects, the possibility of treating such diseases, which targets the influence of the CGMP signal pathway in organisms and is independent of NO, is a promising approach. For the therapeutic stimulation of soluble guanylactocyclase, 10 compounds have been used so far exclusively compounds, such as organic nitrates, whose efficacy is based on NO. This is formed by bioconversion and activates soluble guanylate cyclase attacking the central heme iron atom. In addition to the side effects, the development of tolerance is decisively. disadvantage of this type of treatment. 15 In recent years, some substances have been described that directly stimulate soluble glunylatocyclase, that is, without prior release of NO, such as 3- (5'-hydroxymethyl-2'-furyl) -1-benzylindazole [ YC-1; Wu et al., Blood 84 (1994), 4226; Mulsch et al., Brit. J. Phannacol. 120 (1997), 681], fatty acids [GoIdberg et al., J. Biol. Chem. 252 (1977), 20 1279], diphenyliodonium hexafluorphosphate [Pettibone et al., Eur J. Phannacol. 116 (1985), 307], isoliquiritigenin [Yu et al., Brit. J. Phannacol. 114 (1995), 1587] and various substituted pyrazole derivatives (WO 98/16223). As soluble guanylate cyclase stimulators are disclosed in WO 00/06569 fused pyrazole derivatives, and WO 03/095451 3- 25 carbamate substituted pyrimidinylirazolopyridines. The object of the present invention was the preparation of new substances, which act as stimulators of soluble glunylate cyclase and present an equal or improved therapeutic profile compared to the compounds known in the state of the art, for example, with a view to it suggests its in vivo properties, such as its pharmacokinetic and pharmacodynamic behavior and / or its dose-activity relationship. The present invention provides compounds of the general formula (j)
F AS 'f "' _ NH2 H'NO, = ('N-R' 0 '
OH, C (I), in which R1 represents hydrogen or (C1-C4) -a | qui | a, (C1-C4) -a | qui | a may be replaced by one or two + substituents, independent one on the other, selected from the group fluorine and tri-.5 fluoromethyl, as well as their N-oxides, salts, solvates, salts of N-oxides and solvates of N-oxides and salts.
V Compounds according to the invention are the compounds of formula (I) and their N-oxides, salts, soIvates and solvates of N-oxides and salts, the '10 compounds covered by formula (I), of the formulas specified here may thereafter, and their N-oxides, salts, solvates and solvates of the N-oxides and salts, as well as the compounds covered by formula (I) and specified here below as working examples and their N-oxides, salts, solvates and solvates of N-oxides and their salts, provided that the compounds a-15 bleached by formula (I) and specified here after are not yet N-oxides, salts, solvates and solvates of N-oxides and salts. As salts in the context of the present invention, physiologically compatible salts of the compounds according to the invention are preferred. Also included are salts that are not properly suitable for
For pharmaceutical applications, but can be used, for example, for the isolation or purification of the compounds according to the invention. Physiologically compatible salts of the compounds according to the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, for example, hydrochloric acid salts, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid, and benzoic acid.
Physiologically compatible salts of the compounds according to the invention also include salts of conventional bases, for example, and preferably alkali metal salts (e.g. sodium and potassium salts), alkaline earth metal salts (e.g. eg calcium salts and magnesium salts) and ammonium salts, ammonia derivatives or organic amines containing 1 to 16 carbon atoms, as an example and preferably eti. lamina, diethylamine, triethylamine, ethyldiisopropyl amine, monoethanolamine,
. diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine. "In the context of the present invention, solvates are those forms of the compounds according to the invention which, in the solid or liquid state, form a complex by coordination with solvent molecules.
Hydrates are a special form of solvates, in which coordination occurs with water.
As solvates, hydrates are preferred in the context of the present invention.
Depending on their structure, the compounds according to the invention can exist in different isomeric forms, i.e. in the form of
25 configurational isomers, or if appropriate also the conforming isomers (enanciomers and / or diastereomers, including those in the case of atropisomers). The present invention therefore encompasses enanciomers or diastereomers and their respective mixtures.
From these mixtures of e-nanciomers and / or diastereomers can be isolated in a known manner from uniform stereoisomeric constituents; Chromatographic processes are preferably used for this, in particular HPLC chromatography in an achiral and / or chiral phase.
As long as the compounds according to the invention can take the tautomeric form, the present invention covers all tautomeric forms.
The present invention also covers all isotopic variants
5 suitable tips of the compounds according to the invention.
It can be understood here, for an isotopic variant of a compound according to the invention, a compound in which at least one atom, in the compound according to the invention, has been exchanged for another atom of equal atomic number, however with another one atomic mass than atomic mass
10 usual or principal in nature, which usually or predominantly occurs in nature.
Examples of isotopes, which can be incorporated into a compound according to the invention, are those of hydrogen, carbo-. no, nitrogen, oxygen, matches, sulfur, fluorine, chlorine, bromine and iodine, such
. such as 2H (deuterium), 3j-j (tritium), 13ç, "C, 15N, '7O,' 8O, 32p, 33p, 33S, 3'S, 35S, 15 * S, 18F, 36çj, 82Br, 123j, 124j, 129j and 131j.
Certain isotopic variants of the compound according to the invention, especially those in which a
"or more radioactive isotopes have been incorporated, they may be useful, for example, for examining the mechanism of action or the distribution of the active compound in the body; due to comparability and preparability
20 easily easy, compounds marked with isotopes 3H or 1'ç are especially suitable here. In addition, the incorporation of isotopes, such as deuterium, may lead to certain therapeutic advantages, as a consequence of the greater metabolic stability of the compound, for example, an extension of the half-life in the body or a reduction in the
25 va requested; such modifications of the compounds according to the invention may therefore, if appropriate, also constitute a preferred embodiment of the present invention.
Isotopic variants of the compounds according to the invention can be prepared by processes known to experts, for example, by the processes described below and
30 processes described in the working examples, in which the corresponding isotopic modifications of the respective reagents and / or their starting compounds are employed.
In addition, the present invention also encompasses prodrugs of the compounds according to the invention.
The term "prodrugs" here refers to compounds which can be properly biologically active or inactive, however during their residence time in the body they are con-
5 poured into the compounds according to the invention (for example, metabolically or hydrolytically). In the context of the present invention, unless otherwise specified, the substituents are defined as follows: Alkyl represents, in the context of the present invention, a radical
10 straight or branched alkyl containing 1 to 4 carbon atoms.
For example, and preferably, mention is made of: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, 1-methylpropyl, tert-butyl. . Halogen represents, in the context of the present invention, fluorine,
. chlorine, bromine and iodine. 15 If radicals in the compounds according to the invention are substituted, the radicals can be, as long as nothing cliferous is specified,
"monosubstituted or polysubstituted.
In the context of the present invention, all radicals that occur more than once are defined independently of each other.
A substitution by one, two or three substituents
The same or different is preferred.
In the context of the present invention, compounds of formula (I) in which R1 represents hydrogen or methyl, where methyl can be substituted by a trifluoromethyl substituent, are preferred.
25 Ia,. as well as their salts, solvates and solvates of the salts.
Particularly preferred in the context of the present invention, are the following compounds of the formula (I): {4,6-diamino-2- [5múor-1- (2-fjuorbenzi |) -1H-pyraz | o [3,4-b ] pyridin-
30 3-yl] pyrimidin-5-yl} methyl {4,6-diamino-2- [5-fluoro-1- (2-¶uorbenzyl) -1 H-pyrazolo [3,4-b] pyridin- 3-yl] pyrimidin-5-yl} methyl methylcarbamate
{4,6-diamino-2- [5-fluoro-1- (2-fluorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-3-i |] pyrimdin-5-in (2,2, Methyl 2-trjf1uorethyl) {4,6-diamino-2- [5-¶úor-1- (2-Auorbenzyl) -1H-pyrazolo [3, Zb] pyridin-3-yl] pyrimidin-5-yl} carbamate methyl hydrochloride 5 {4,6-d jamino-2- [5-¶úor-1- (2-f | uorbenzi |) -1 H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin -5-yl} carbamate methyl sulfate {4,6-diamino-2- [5múor-1- (2-f] uorbenzi |) -1H-pyrazole [3,4-b] pyridin-3-yl] pyrimidin- 5-yl} carbamate methyl phosphate {4,6-diamino-2- [5-núor-1- (2-¶uorbenzi |) -1H-pyrazolo [3,4-b] pyridin-
10 3-yl] pyrimidin-5-yl} carbamate methyl mesylate methyl {4,6-diamino-2- [5-fluoro-1- (2-¶uorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin-5-yl} carbamate ethane-1,2-disulfonate. {4,6-diamino-2- [5-núor-1- (2-¶uorbenzi |) -1 H-pyrazolo [3,4-b] pyridin-
. 3-yl] pyrimidin-5-yl} carbamate methyl maleate 15 {4,6-diamjno-2- {5múor-1- (2-fluorbenzi |) -1H-pyraz | o [3,4-b] pyridin- 3-yl] pyrimidin-5-yl} carbamate methyl nitrate "The definitions of the radicals individually specified in the respective combinations or preferred combinations of the radicals are, regardless of the respective combinations of the specified radicals, 20 also replaced as desired by the definitions of the radicals other combinations.
Particularly preferred combinations are two or more of the preferred ranges mentioned above.
Another object of the invention is a process for preparing the
25 compounds according to the invention of the formula (I) characterized by the fact that, ueocom, ostodaf) ') jCiÜ
(ll)
[A] is reacted in an inert solvent in the presence of hexabutiles and an appropriate palladium catalyst with intermediate formation of a kind of tin with the compound of the formula (lll) Cl ,,, J> t: N ,, o " M (,,,), to give the compound of the formula (lV) Fr) == ^^., I ~ A4 "
W «r '_ NH, H2" ", µo-.
° (lV), 5 this is then reduced in an inert solvent with a reducing agent. ,, o ,,,. Do,.,., O, m.,)) 7) r '_ NH, H, N " NH2 (V) this is then reacted in the presence of an appropriate base with or without solvent with chloroformic acid methylester to form the compound of the formula (IA)
Fr, i »r 'H, N" _ NH NH, ° = (/
The H3C (IA), or - [B] the compound of the formula (ll) is reacted in an inert solvent - with copper cyanide to form the compound of the formula (Vl), Áy-: ítj CN (Vl), this is then converted, under acidic conditions, to the compound 5 of the formula (VII) '") == ,, í'; ç> Hnh H, N x H, CCO2H (V11), this is then reacted in an inert solvent in the presence of an appropriate base with the compound of the formula (Vlll)
"'" r "N,> N C (Vlll) to give the compound of the formula (lX) Fr) == .-": "d"
F r "_ NH," H, N ", h P N '
U / C ~~ / (lX), which is then reduced by an inert solvent in the presence of an appropriate reducing agent to give compound N), and this is subsequently reacted according to the process [A] to give 5 the compound (IA), or [C] the compound of the formula (IA) is reacted in an inert solvent in the presence of an appropriate base with a compound of the formula (X) R'mx '(X) , 10 on wed! R1a represents (C1-C4) -alkyl, where (C1-C4) -here can be substituted by one or two substituents independently of each other selected from the fluorine and trifluoromethyl group, q 15 and
X 'represents a leaving group, for example, halogen, in particular bromine or iodine, trichloromethanesulfonate, mesylate or tosylate to form a compound of the formula (I-B) F ) == íY: N
F N ^ "_ NH, '" O, = (í ~ /
The H3C (IB) m in which R1a has the meaning given above, m the compounds resulting from formulas (IA) and (IB), appropriated with (i) the appropriate solvents and / or (ii) acids or bases to form its solvates, salts and / or soIvates of the salts. Inert solvents for the process step (Il) + (lll) -> (lV) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers, such as diethyl ether, dioxans, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents, such as dimethylformamide (DMF) , dimethylsulfoxide (DMSO), N, NLdimethi | propylene urea (DMPU), dimethylacetamide, N-methylpyrrolidone (NMP), pyridine, acetonitrile, sulfolane or also water. It is also possible to use mixtures of the mentioned solvents. Preference is given to dioxane. Palladium catalysts suitable for the (ll) + (lll) -> (lV) process step are, for example, palladium on activated carbon, palladium acetate (ll), tetracis (triphenylphosphine) palladium (0), bis chloride (triphenylphosphine) palladium (ll), bis (acetonitrile) palladium (ll) chloride and the [1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (ll) / dichloromethane complex, if appropriate in combination with phosphane binders additional, such as, for example, (2-biphenyl) di-tert-butylphosphine, dicyclohexyl [2 ', 4', 6'-tris (1- 5 methylethyl) biphenik2-ü] phosphane (XPHOS), bis ( 2-phenylphosphinophenyl) ether (DPEphos) or 4,5-bis (diphenylphosphino) -9,9-dimethylxanthene (Xantphos) [cf., for example, Hassan J. et al., Chem. Rev. 102, 1359-1469 (2002)]. Preferably, tetracis (triphenylphosphine) palladium (0) is used. The (Il) + (lll) -> (lV) reaction is usually carried out in a temperature range of + 20 ° C to + 180 ° C, preferably from + 50 ° C to + 120 ° C, if appropriate in a microwave. The reaction can be carried out at atmospheric pressure, high or low (for example, from (0.5 to 5 bar)). In general, m works at atmospheric pressure. + Reductions (lV) ~ N) and (lX) -3 N) occur in the presence of an appropriate catalyst in an inert solvent in a temperature range of + 20 ° C to + 40 ° C under atmospheric pressure of hydrogen. Inert solvents for the (lV) -> N) and (lX) ~ N) reductions are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents, such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N, NLdimeti | propi | enourea (DMPU), N-methylpyrrolidone (NMP), pyridine, acetonitrile or also water. It is also possible to use mixtures of the mentioned solvents. DMF and pyridine are preferred.
25 Suitable catalysts for the reactions (lV) -> N) and (lX) -> N) are, for example, palladium on activated carbon, pyatin on carbon, palladium hydroxide or Raney nickel. The reductions (IV) -> N) and (lX) -> N) can be carried out by alternatively using a metal or metallic salts, such as, for example, iron, zinc or tin (ll) chloride in an appropriate acid, such as, for example, hydrochloric acid hydrogen chloride, sulfuric acid, phosphoric acid or acetic acid in a temperature range of + 20 ° C to
+ 140 ° C.
Inert solvents for process step N) -> (IA) are, for example, alcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, tetra -
5 hydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, trichlorethylene or chlorobenzene, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or fractions of oil mineral, or other solvents, such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO),
10 N, NLdimethi | propylenourea (DMPU), N-methylpyrrolidone (NMP), acetonitrile or also water.
It is also possible to use mixtures of the solvents mentioned.
Dimethylformamide and toluene and a mixture of dimethylformamide and toluene are also preferred.
Suitable bases for process step N) -> (I-A) are hi-. 15 alkaline droplets, such as sodium hydride, alkaline hydroxides, such as, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide,
"alkaline carbonates, such as lithium carbonate, sodium carbonate, potassium carbonate, or cesium carbonate, alkaline hydrogen carbonates, such as sodium hydrogen carbonate or potassium hydrogen carbonate,
20 alkaline alcoholates, such as methanolate, sodium or potassium methanolate, sodium ethanolate or potassium ethanolate or potassium tert-butylate, or organic amines, such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) or 1,5-diazabicycle [4.3.0] non-5-ene (DBN). Pyridine is preferred. 25 The N) reaction »(I-A) is generally carried out in a temperature range of -1 ° C to + 30 ° C, preferably from 0 ° C to + 20 ° C.
The reaction can be carried out at atmospheric pressure, high or low (for example, from (0.5 to 5 bar)). The reaction is usually carried out at atmospheric pressure
rich. Inert solvents for process step (ll) ~ (Vl) are, for example, ethers, such as diethyl ether, dioxane, tetrahydrofuran, dimethyl ether glycol or diethylene glycol dimethyl ether, hydrocarbons, such as benzene,
xylene, toluene, hexane, cyclohexane or fractions of mineral oil, or other solvents, such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N, NLdimeti | propi | enourea (DMPU), N-methylpyrrolidone (NMP) , pyridine or acetonitrile.
It is also possible to use mixtures of the solvents mentioned
5 strokes.
Preference is given to DMSO.
The reaction (ll) -> (Vl) is usually carried out in a temperature range of + 20 ° C to + 180 ° C, preferably from + 100 ° C to +160 "C, if appropriate in a micro -waves.
The reaction can be carried out at atmospheric, atmospheric or reduced pressure (for example, from (0.5 to 5 bar)). Area-
lO tion is generally performed at atmospheric pressure.
The reaction (Vl) -> (VIl) occurs according to the processes known to the specialist in a two-step process, first under the formation of the iminoester with sodium methanolate in methanol at 0 ° C to + 40 ° C
- and subsequently nucleophilic addition of an ammonia equivalent, such as, for example, ammonia or ammonium chloride in acetic acid with amidine formation (V11) from +50 to + 150 ° C.
Inert solvents for the (Vll) + (Vlll) -> (lX) process step are alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol
20 dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mineral oil fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO) , N, N'dimethylpropylene urea (DMPU), N-methylpyrrolidone (NMP), pyridine, acetonitrile or also water.
It is also possible to use mixtures of
25 solvents mentioned.
Preference is given to DMF.
Suitable bases for the process step (Vll) "(Vlll) - * (lX) are alkali hydroxides, such as, for example, lithium hydroxide, sodium hydroxide or potassium hydroxide, alkaline carbonates, such as carbonate of lithium, sodium carbonate, potassium carbonate or cesium carbonate,
30 alkaline hydrogen carbonates, such as sodium hydrogen carbonate or potassium hydrogen carbonate, alkaline alcoholates such as sodium methanolate or potassium methanolate, sodium ethanolate or potassium ethanolate
tassium or potassium tert-butylate, or organic amines, such as triethylamine, diisopropylethylamine, pyridine, 1,8-diazabicyclo [5.4.0] undec-7-ene (DBU) or 1,5-diazabicyclo [4.3 .0] non-5-ene (DBN). Preference is given to triethylamine.
The reaction (VII) + N |) -> (lX) is generally carried out in a temperature range 5 from + 20 ° C to + 150 ° C, preferably from + 80 ° C to +120 "C, if appropriate in a microwave. The reaction can occur at atmospheric pressure, high or reduced (for example, from (0.5 to 5 bar)). In general, it is worked at atmospheric pressure. The compound of the formula ( Vlll) can be prepared analogously 10 to the literature LFCavalieri, jFTanker, A.8endich, j.Am.Chem.Soc., 1949, 71,
533. Inert solvents for reaction (IA) ~ (IB) are, for example, halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon trachloride, trichlorethylene or chlorobenzene, ethers, such as diethyl 15 ether, dioxane, tetra -hydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, or other solvents, such as dimethylformamide (DMF), "dimethyl sulfoxide (DMSO), N, NLdimethi | propylenourea (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile Preference is given to tetrahydrofuran.
Suitable bases for the process step (IA) -> (IB) are 20 alkaline hydrides, such as potassium hydride or sodium hydride, alkaline carbohydrates, such as lithium carbonate, sodium carbonate, potassium carbonate or carbonate cesium, alkaline hydrogen carbonates, such as sodium hydrogen carbonate or potassium hydrogen carbonate, alkaline alcoholates, such as sodium methanolate or potassium methanolate, sodium ethanolate or potassium ethanolate or potassium tert-butylate, a - mides, such as sodium amide, Htiobis (trimethylsilyl) amide, sodium bis (trimethylsil) amide or potassium bis (trimethylsilyl) amide or lithiodiisopropyl amide, organometallic compounds, such as butylthio or phenylithium, or organic amines, such as triethylamine, diisopropyl ethylamine, pyridine, 1,8-30 diazabicyclo [5.4.0] undec-7-ene (DBU) or 1,5-diazabicyclo [4.3.0] non-5-eno (DBN). Preference is given to Htiobis (trimethylsilyl) amide, sodium bis (trimethylsilyl) amide and sodium hydride.
The (I-A) ~ (I-B) reaction is generally carried out in a temperature range of -78 ° C to + 40 ° C, preferably from 0 ° C to + 20 ° C. The reaction can occur at atmospheric pressure, high or low (for example, from (0.5 to 5 bar)). In general it works at atmospheric pressure.
5 The described preparation processes can be illustrated by the following synthesis scheme (Schemes 1 to 3): Scheme 1) IH, rb "A: 3r '°' '_C ^^ INmN,"'. f ^ A ~ // n, i ~ ~ {"'a) n, T" n') 1 _ NH, H, N " NO, -" ^ Ç, ';' , ÁYJ <~~ 1 ^ _ ')' 7 N ,,> = {"'H2N NH,'" "tr ° °, 0 H, C [a): Pd (PPh3) 4, hexabutyltin; b) H2, Pd -C; C) methyl chloroformate, pyridine].
10
Figure 2 f f f Y " ÁJJm fUj", Á "X :: n '" i / k = NH H2N x h, ccq, h f
) = f f = "> n '" «/) ^^
"". , A> - {',. í'X :: N ')': J, Lnh, ')' D, nh, H2N " n = n, h, n" Kh,
'[a): CuCN, DMSO; b): 1. sodium methoxide, methanol 2. ammonium chloride,
. Acetic Acid; c): triethylamine d): H2, Pd-C]. Scheme 3 F.
F,) == ~ "
^ rÁ, sA ^^, JL A, // '. , JI- A _ // "" 'Kn y2Lnh,: ~~ "2'" sj ° h, n ,,,, , jO / J H, C H, C
5 [a) L1HMDS, methyl iodide, THF]. The compound of the formula (ll) can be prepared by cyclizing the compound of the formula (X)
INC | , JLÀ ,,, (,) in an inert solvent with hydrazine hydrate to give the compound of the formula (Xl) Á "7f: N NH2 (Xl), then reacting the same in an inert solvent in the presence of a appropriate Lewis acid Initially with isopentyl nitrite 5 to form the corresponding diazonium salt and then converting it "directly with sodium iodide to form the formula compound (Xll)
F ^ Á / iN and F "Í i (Xll)
W and then reacting it next in an inert solvent in the presence of an appropriate base with the compound of the formula (Xlll), iC Brl (Xlll).
Inert solvents for the process step (X) -> (Xl) are alcohols, such as methanol, ethanol, n-propanol, isopropanol, n-butanol, tert-butanol or 1,2-ethanediol, ethers, such such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or mining oil fractions) or other solvents, such as dimethylformamide ( DMF), dimethyl sulfoxide (DMSO), N, NL-dimethylpropylenourea (DMPU), N-methylpyrrolidone (NMP), pyridine, acetonitrile or also water. It is also possible to use mixtures of the mentioned solvents. 1,2-ethanediol is preferred.
The (X) ~ (Xl) reaction is usually carried out in a temperature range of + 60 ° C to + 200 ° C, preferably from +120 "C to + 180 ° C. The reaction can be carried out at atmospheric pressure, elevated or reduced (for example, (0.5 to 5 bar)). In general, it is operated at atmospheric pressure.
5 Inert solvents for a reaction (Xl) -> (X11) are, for example, halogenated hydrocarbons, such as dichloromethane, trichloromethane, tetrachloromethane, trichlorethylene or chlorobenzene, ethers such as diethyl ether, dioxane, tetrahydrofuran, dimethyl ether glycol or diethylene glycol dimethyl ether, or other solvents, such as dimethylformamide (DMF), 10-dimethyl sulfoxide (DMSO), N, NLdimethi | propi | enourea (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile. DMF is preferred. Lewis acids suitable for the process step (Xl) -> n (X11) are the boron trifluoride / diethyl ether complex, cerium nitrate (LV). ammonium (CAN), tin (II) chloride, lithium perchlorate, zinc chloride 15 (ll), indium chloride (lll) or indium bromide (Ill). The boroldethyl ether trifluoride complex is preferred. "The reaction (Xl) -> (Xll) is generally carried out in a temperature range of -78 ° C to + 40 ° C, preferably from 0 ° C to + 20 ° C. The reaction can occur at atmospheric pressure, elevated or reduced (for example, from 20 (0.5 to 5 bar)). In general, atmospheric pressure is used. Inert solvents for the reaction (Xll) + (Xlll) -> (Il) are, for example, halogenated hydrocarbons, such as dichloromethane, trichloromethane, carbon tetrachloride, trichlorethylene or chlorobenzene, ethers, such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or diethylene 25 glycol dimethyl ether, or other solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), N, NLdimethi | propylenourea (DMPU), N-methylpyrrolidone (NMP), pyridine or acetonitrile. DMF is preferred. Bases suitable for the process step (Xll) + (Xlll) -r> (ll) are alkaline hydrides, such as potassium hydride or sodium hydride, 30 alkaline carbonates, such as lithium carbonate, sodium carbonate , potassium carbonate or cesium carbonate, alkaline hydrogen carbonates, such as sodium hydrogen carbonate or potassium hydrogen carbonate,
alkaline alcoholates, such as sodium methanolate or potassium methanolate, sodium ethanolate or potassium ethanolate or potassium tert-butylate, amides, such as sodium amide, lithium bis (trimethylsilyl) amide, bis (trimethylsilyl) amide sodium or potassium bis (trimethylsilyl) amide or lithium di-5 isopropylamide, organometallic compounds such as butylthio or phenylithio, or organic amines such as triethylamine, diisopropyl ethylamine, pyridine, 1,8-diazabicyclo [5.4. 0] undec-7-ene (DBU) or 1,5-diazabicyclo [4.3.0] non-5-ene (DBN). Cesium carbonate is preferred. The (Xll) + (Xlll) -> (ll) reaction is usually carried out in a temperature range 10 ° C to + 60 ° C, preferably from + 10 ° C to + 25 ° C. The reaction can be carried out at atmospheric pressure, high or low (for example, from (0.5 to 5 bar)). In general, work at atmospheric pressure.
F The preparation process described can be illustrated exemplarily by the following synthesis scheme (Scheme 4): 15 Scheme 4
FCN "'" "a)
N '"±" 1 t' "! ', N. Í'ü NH, b) F ^ ~ 1 -1 f ~~" D! = N "l [a): hydrazine hydrate, 1,2- ethanediol; b): isopentyl nitrite, Nal, THF; b): 2-fluorbenzyl bromide, CS2CO3, DMF;] Another object of the present invention is the compound: 5-f] uor-1- (2-f | uorbenzi |) -3-iodo-1H-pyrazole | o [3,4-b] pyridine
F ^>,, - {"'Another object of the present invention is the compound: 5-fluor-3-iodo-1 H-pyrazolo [3,4-b] pyridine 1N ~ N, HF" ~ í "' Os compounds of the formulas (Ill) and (X111) are commercially obtainable, known from the literature or can be prepared in analogy to "processes known from the literature. "" The compound of formula (X) is known from the Literature [cf., for example, Winn M., J. Med. Chem. 1993, 36, 2676-7688; EP 634 413-A1; CN r 1613849-A; EP 1626045-A1; WO 2009/018415] and can be prepared in analogy to the processes known in the literature or as shown in the following summary diagram (Scheme 5): Scheme 5 Cl · ~ -NC | C | ~ N ~ C | JI i 0 FCN ·) "'" "ÁY"' b) "
O jN ~ Cl INCl fY ^ "> C) FCN
[A): sulfuric acid; b): zinc, methanol, glacial acetic acid; c): trifluoroacetic acid anhydride, dichloromethane]. The compounds according to the invention act as stimulators
soluble guanylate cyclase painters and have an equal or improved therapeutic profile when compared to compounds known in the art such as, for example, their in vivo properties, such as, for example, their pharmacokinetic and pharmacokinetic behavior -
5 macodynamic and / or its dose-activity relationship and / or its safety profile.
They are therefore suitable for the treatment and / or prophylaxis of diseases in men and animals.
The compounds according to the invention lead to vessel relaxation and inhibition of thrombocyte aggregation and lead to
10 a reduction in blood pressure, as well as an increase in coronary blood flow.
These effects are induced by direct stimulation of soluble guanylate cyclase and an increase in intracellular cGMP.
In addition, the compounds according to the invention increase the effect of
. substances increasing the concentration of CGMP, such as, for example, 15 EDRF (endothelium-derived relaxing factor), NO donors, lX protoporphyrin, arachidonic acid or phenylhydrazine derivatives. "The compounds according to the invention are suitable for the treatment and / or prophylaxis of cardiovascular, pulmonary, thromboembolic and fibrotic disorders. 20 The compounds according to the invention can therefore be used in medicines for the treatment and / or prophylaxis cardiovascular disorders, such as, for example, hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular disorders, arrhythmias, atrial and ventricular arrhythmias, as well as conduction disorders, such as, for example, l-lll degree atrioventricular blocks (AB l-lll block), supraventricular tachyarrhythmia, atrial fibrillation, atrial fluoride, ventricular fibrillation, ventricular fluoride, ventricular tachyarrhythmia, Torsade de pointes - tachycardia, atrial extrasystoles and ventricular, extra junctional AV systoles,
30 of Sick-Sinus, syncope, AV nodal reentry tachycardia, Wolff-Parkinson-White syndrome of acute coronary syndrome (CHA), autoimmune cardiac disorders (pericarditis, endocarditis, valvolitis, aortitis, cardiomyopathy-
as), shocks, such as cardiogenic shock, septic shock and anaphylactic shock, aneurysm, boxer cardiomyopathy (premature ventricular contraction (PVC)), for the treatment and / or prophylaxis of thromboembolic disorders and ischemia, such as myocardial ischemia, myocardial infarction, stroke 5, cardiac hypertrophy, transient and ischemic attacks, preeclampsia, inflammatory cardiovascular diseases, spasms of the coronary arteries and peripheral arteries, edema formation, such as, for example, pulmonary edema, cerebral edema, renal edema or edema caused by heart failure, peripheral circulatory disorders, reperfusion damage,
10 arterial and venous thrombosis, microalbuminuria, myocardial insufficiency, endothelial dysfunction, to prevent restenosis, for example, after therapies against thrombosis, percutaneous transluminal angioplasties (PTA), angioplas-. transluminal coronary arteries (PTCA), heart transplants and operations
. bypass, as well as microvascular damage and macrovascular damage i; j (vasculitis), higher levels of fibrinogen and low-density lipoprotein (LDL) as well as increased concentrations of active inhibitor.
"plasminogen pain (PAl-1), as well as for the treatment and / or prophylaxis of erectile dysfunction and female sexual dysfunction.
In the context of the present invention, the term heart failure also includes more specific forms of disease or specific relative types, such as decompensated heart failure, right heart failure, left heart failure, global failure, ischemic cardiomyopathy, cardiomyopathy dilatation, hypertrophic cardiomyopathy, idiopathic cardiomyopathy, congenital heart defects, valve defects
25 cardiac, heart failure associated with heart valve defects, mitral stenosis, mitral insufficiency, aortic stenosis, aortic insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis, pulmonary valve failure, combined heart valve defects, myocardial inflammation (myocarditis), chronic myocarditis, acute myocarditis, 30 viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, alcoholic cardiomyopathy, cardiac storage disorders, and diastolic and systolic heart failure.
In addition, the compounds according to the invention can also be used for the treatment and prophylaxis of arteriosclerosis, metabolism of lipid disorders, hypolipoproteinemias, dyslipidemias, hyperglyceridemia, hyperlipidemia, hypercholesterolemia, abetalipoproteinemi- 5, sitosterolemia, Tangier's disease, adiposity, obesity and combined hyperlipidemia, as well as metabolic syndrome.
Additionally, the compounds according to the invention can also be used for the treatment and / or prophylaxis of primary and secondary Raynaud's phenomena, microcirculatory disorders, 10 audiotherapy, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers in the extremities, gangrene, CREST syndrome, erythematosis, onychomycosis, rheumatic disorders and pa-. to promote wound healing.
The compounds according to the invention are furthermore suitable. 15 suitable for the treatment of urological disorders, such as, for example, benign prostate syndrome (BPS), benign prostatic hyperplasia (BPH),
"benign prostatic hypertrophy (BPE), voiding dysfunction (BOO), lower urinary tract syndromes (LUTS, including Feline Urological Syndrome (FUS)), disorders of the urogenital system including neuro-genic overactive bladder (OAB) and ( CI), urinary incontinence (Ul), such as, for example, mixed urinary incontinence, urinary urinary incontinence, stress urinary incontinence or overflow urinary incontinence (MUI, UUI, SUl, OUl), pelvic pain, benign disorders and malignant organs of the male and female urogenital system.25 The compounds according to the invention are furthermore suitable for the treatment and / or prophylaxis of kidney diseases, in particular acute and chronic renal failure, as well as acute and chronic kidney failure.
In the context of the present invention, the term renal failure encompasses both acute and chronic manifestations of renal failure, as well as underlying or related renal diseases, such as renal hypoperfusion, intradialitic hypotension, obstructive uropathy, glomerulopathies, glomerulonephritis , acute glomerulonephritis,
sclerosis, tubulointerstitial diseases, nephropathic diseases, such as primary and congenital kidney disease, nephritis, immune kidney diseases, such as renal graft rejection and immunocomplex-induced kidney diseases, toxic agent-induced nephropathy, 5 agent-induced nephropathy contrast, diabetic and non-diabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertensive nephrosclerosis and nephrotic syndrome, which can be characterized by diagnosis, for example, by a- normally reduced creatinine and / or water excretion, urea concentrations , abnormally elevated blood, nitrogen, potassium and / or creatinine, modified renal enzyme activity, such as, for example, glutamyl synthase, altered urine osmolarity or urine volume, elevated microalbuminurea, macroalbuminurea, lesions in glomeruli and arterioles, tubular dilation, hyperphosphatemia and / or need for dialysis.
The present invention
. also comprises the use of the compounds according to the invention for the treatment and / or prophylaxis of sequelae of renal failure, for example, pulmonary edema, heart failure, uremia, anemia, electrolyte disturbances
"toxicities (e.g., hyperkalaemia, hyponatremia) and disturbances in bone and carbohydrate metabolism.
In addition, the compounds according to the invention are also suitable for the treatment and / or prophylaxis of asthmatic diseases, pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), including left heart disease, HIV, sickle cell disease, thromboembolism (CTEPH), sarcoidosis, COPD or pulmonary hypertension associated with pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), acute lung injury (ALI), alpha-l deficiency -antitrypsin (AATD), pulmonary fibrosis, pulmonary emphysema (for example, pulmonary emphysema induced by cigarette smoke) and cystic fibrosis (CF). The compounds described in the present invention also represent active compounds for the control of diseases of the central nervous system, which are characterized by disorders of the NO / cGMP system.
They are especially suitable for improving perception,
concentration ability, learning capacity or memory performance after cognitive disorders, such as those that occur especially in situations / diseases / syndromes, such as mild cognitive disorders, age-associated learning and memory disorders, associated memory losses age, vascular dementia, brain-cranial trauma, stroke, post-stroke dementia (post-stroke dementia), post-traumatic brain-cranial trauma, impaired general concentration, impaired concentration in children with learning and memory problems, Alzheimer's, dementia with Lewy corpuscles, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear paralysis, dementia with corticobasal degeneration, arniolateral sclerosis (ALS), Huntington's disease, demyelination , multiple sclerosis, thalamic degeneration, Creutz- dementia. feld-jacob, HlV dementia, schizophrenia with dementia or U Korsakoff psychosis. They are also suitable for the treatment and / or prophylaxis of disorders of the central nervous system, such as anxiety states, "tension and depression, sexual dysfunctions related to CNS and sleep disorders and substances for the control of pathological disorders of food intake. , stimulants and addictive substances.
In addition, the compounds according to the invention are also suitable for the control of cerebral irrigation and thus represent effective agents for the control of migraine. They are also suitable for the prophylaxis and control of sequelae of cerebral infarction (Apoplexia cerebri), such as stroke, cerebral ischemia and craniocerebral trauma.
The compounds according to the invention can also be used to control pain and tinnitus. In addition, the compounds according to the invention have an anti-inflammatory action and can therefore be used with anti-inflammatory agents for the treatment and / or prophylaxis of septicemia (SIRS), multiple organ failure (MODS, MOF ), inflammatory kidney disorders, chronic intestinal inflammation (IBD, Crohn's disease, UC), pancreatitis, peritonitis, rheumatoid disorders, dermatological inflammatory diseases and ophthalmic inflammatory diseases.
In addition, the compounds according to the invention can also be used for the treatment and / or prophylaxis of autoimmune diseases.
In addition, the compounds according to the invention are suitable for the treatment and / or prophylaxis of fibrotic diseases of Organs internal organs, such as, for example, the lung, heart, kidneys, bone marrow, and in particular the liver, as well as dermatological fibrosis and fibrotic ophthalmic diseases.
In the context of the present invention, the term fibrotic diseases includes in particular the following terms: liver fibrosis,
10 liver cirrhosis, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage resulting from diabetes, bone marrow fibrosis and similar fibrotic diseases, scleroderma, mor-. ugly, keloids, hypertrophic scars (also after the procedure
- surgical procedures), pure, diabetic retinopathy, proliferative vitreoretinopathy and connective tissue diseases (eg sarcoidosis). In addition, the compounds according to the invention are approved
"suitable for the control of postoperative scars, for example, as a result of glaucoma operations.
The compounds according to the invention can also be used cosmetically on aged and keratinized skin.
In addition, the compounds according to the invention are suitable for the treatment and / or prophylaxis of hepatitis, neoplasms, osteoporosis, glaucoma and gastroparesis.
Another object of the present invention is the use of compounds of
25 according to the invention for the treatment and / or prophylaxis of diseases, in particular the diseases mentioned above.
Another object of the present invention is the use of the compounds according to the invention for the treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia,
30 vascular diseases, kidney failure, thromboembolic diseases, diseases, fibrotic and arteriosclerosis.
Another object of the present invention are compounds according to the invention for use in a method for the treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular diseases, renal failure, thromboembolic diseases , fibrotic diseases and arteriosclerosis. Another object of the present invention is the use of the compounds according to the invention for the production of a medicament for the treatment and / or prophylaxis of diseases, in particular the diseases mentioned.
Another object of the present invention is the use of the compounds according to the invention for the preparation of a medicament for the treatment
l The treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular diseases, renal failure, thromboembolic diseases, fibrotic diseases and atherosclerosis. . Another object of the present invention is a process for treating
. and / or prophylaxis of diseases, in particular of the diseases mentioned above, using an effective amount of at least one compound according to the invention. "Another object of the present invention is a process for the treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disorders, heart failure
20 renal, thromboembolic diseases, fibrotic diseases and atherosclerosis using an effective amount of at least one of the compounds according to the invention. The compounds according to the invention can be used individually or, if necessary, in combination with other compounds.
25 active posts.
Another object of the present invention are drugs, containing at least one of the compounds according to the invention and one or more other active compounds, especially for the treatment and / or prophylaxis of the diseases mentioned above.
As combinations of appropriate active compounds can be mentioned as an example and
30 ference: · organic nitrates and NO donors, for example, sodium nitroprusiate, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate
bida, molsidominas or SIN-I, and inhaled NO; · Compounds that inhibit the breakdown of cyclic guanosine monophosphate (cGMP), such as, for example, phosphodiesterase (PDE) 1, 2 and / or 5 inhibitors, in particular PDE 5 inhibitors, such as sildenafil, 5 vardenafil and tadalafil; · Agents with antithrombotic effect, for example, and preferably from the group of inhibitors of platelet aggregation, anticoagulants or profibrinolytic substances; · Active blood pressure reducing compounds, for example, and preferably from the group of calcium antagonists, angiotensin All antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, blockers of beta-. receptors, mineralcorticoid receptor antagonists and diuretics;
- and / or 15 · active compounds that alter the metabolism of lipids, for example, and preferably from the group of thyroid receptor agonists,
"cholesterol synthesis inhibitors, such as, for example, and preferably, HMG-COA reductase inhibitors or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR-alpha 20 agonists, PPAR - gamma and / or PPAR-delta, cholesterol absorption inhibitors, lipase inhibitors, polymeric bile acid adsorbents, bile acid reabsorption inhibitors and Iipoprotein (a) antagonists; antithrombotic activity preferably compounds from the group of inhibitors of aggregation of thrombocytes, anticoagulants or profibrinetic substances.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a thrombocyte aggregation inhibitor, as for example, and preferably aspirin, clopidogrel, ticlopidine or dipyridamole. In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a thrombin inhibitor, for example, and preferably ximelagatran, dabi-
gatran, melagatran, bivalirudin or clexane.
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a GP11bMIa antagonist, for example, and preferably tirofiban or
5 abciximab.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a factor Xa inhibitor such as, and preferably, rivaroxaban (BAY 59-7939), DU-176b, apixaban, otamixaban, fidexaban, razaxaban, fondapa-
10 rinux, idraparinux, PMD-3112, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428. In a preferred embodiment of the invention the composites. according to the invention are administered in combination with hepa-
. rine or a low molecular weight heparin (LMW) derivative. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a
"vitamin K antagonist, for example, and preferably coumarin.
Blood pressure reducing agents are preferably compounds of the group of calcium antagonists, angiotensin antagonists.
20 All sign, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha receptor blockers, beta receptor blockers, mineralocorticoid receptor antagonists, and diuretics.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a
Calcium antagonist, such as, and preferably nifedipine, amylipine, verapamil or diltiazem.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with an alpha-1 receptor blocker, for example, and preferably termically.
30 fate.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a beta receptor blocker, such as, and preferably propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol , bupranolol, metipranolol, nadolol, mepindolol, carazalol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landi-
olol, nebivolol, epanolol or bucindolol.
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with an angiotensin All antagonist, for example, and preferably Iosartan, candesartan, valsartan ,. telmisartan or embusartan. '
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with an ACE inhibitor, such as, for example, and preferably enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
In a preferred embodiment of the invention the composites
i5s according to the invention are administered in combination with an endothelin antagonist P, for example, and preferably bosentan,
"darusentan, ambrisentan or sitaxsentan.
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a renin inhibitor, for example, and preferably aliskiren, SPP-600 or SPP-800. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a mineralocorticoid receptor antagonist, such as, and
spironolactone or eplerenone transfer.
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a diuretic loop, such as, for example, furosemide, torasemide, bumetanide and piretanide, with potassium-sparing diuretics, such as, for example, example,
amiloride and triamterene, with aldosterone antagonists such as, for example, spironolactone, potassium canrenoate and eplerenone as well as thiazide diuretics, such as hydrochlorothiazide, chlorothalidone, xipa-
mida and indapamide.
Preferably, lipid metabolism modifying agents are comprised, preferably, of the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors, 5 such as HMG-COA reductase inhibitors or stenosis synthesis inhibitors. , ACAT inhibitors, MTP inhibitors, PPAR-alpha, PPAR-gamma and / or PPAR-delta agonists, cholesterol absorption inhibitors, polymeric bile acid additives, bile acid reabsorption inhibitors, Iipase inhibitors and antagonists lipoprotein (s). In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a CETP inhibitor, such as, and preferably dalcetrapib, BAY 60-. 5521, anacetrapib or CETP vaccine (CET1-1). In a preferred embodiment of the invention the composites. 15 in accordance with the invention are administered in combination with a thyroid receptor agonist such as, for example, and preferably, D- "thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axithyrome ( CGS 26214) In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a statin class HMG-CoA reductase inhibitor, such as, and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a
25 squalene synthesis inhibitor, as for example, and preferably BMS-1 88494 or TAK-475. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with an ACAT inhibitor, for example, and preferably avasimib, melamine, pactimib, eflucimib or SMP-797. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with an MTP inhibitor, as for example, and preferably implitapide, BMS-201038, R-103757 or JTT-130. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a PPAR-gamma agonist, for example, and preferably pioglitazone or rosiglitazone.
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a PPAR-delta agonist, as for example, and preferably GW 501516 10 or BAY 68-5042. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with one. cholesterol absorption inhibitor such as, and preferably eze-
- timibe, tiqueside or pamaqueside. In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a "lipase inhibitor, such as orlistat.
In a preferred embodiment of the invention, the compounds according to the invention are administered in combination with a polymeric biliary acid adsorbent, such as, and preferably cholestyramine, colestipol, colesolvam, CholestaGel or colestimide.
In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a bile acid reabsorption inhibitor, for example, and preferably ASBT inhibitors (= IBAT), for example , AZD-7806, S-8921, AK-105, BARI-1741, SC-435 or SC-635 In a preferred embodiment of the invention the compounds according to the invention are administered in combination with a lipoprotein antagonist (s) such as, and preferably, gemca-30 bene calcium (Cl-1027) or nicotinic acid.
The present invention further provides medicaments that comprise at least one compound according to the invention, typically together with one or more pharmaceutically suitable or more inert, non-toxic excipients, and their uses for the purposes mentioned above. The compounds according to the invention can act systemically and / or locally. For this purpose they can be administered in an appropriate manner, for example, by oral, parenteral, pulmonary, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, optic, or as an implant or stent. The compounds according to the invention can be administered in forms of administration appropriate for these routes of administration. For oral application are appropriate, according to the technique
R above, administration forms that rapidly release the compounds according to the invention and / or, in a modified way, that contain the compounds according to the invention in crystalline and / or amorphous form and / or dissolved form, for example, tablets (coated or uncoated tablets, for example, with dissolution resistant to gastric juice or delayed, or insoluble coatings that control the release of the compound according to the invention), tablets or films / wafers that 20 rapidly disintegrate in the oral cavity, films / lyophilates or capsules (for example, hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions. through a 25-step deviation of resorption (eg intravenously, intra-arterially, intracardially, intraspinally or intralumbally) or by maintaining a resorption (eg intramu scularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). For parenteral administration, injection and infusion preparations in the form of solutions, suspensions, emulsions, freeze-dried or sterile powders are suitable as forms of application, among others. For other routes of application, forms of inhalable medications are appropriate, suitable examples are forms of inhalable medications (including powdered inhalers, nebulizers), nasal drops, solutions or sprays, tablets, films / wafers or capsules for lingual, sublingual or buccal administration, suppositories, prepared for the ears or
5 eyes, vaginal capsules, aqueous suspensions (lotions, stirring mixtures), lipid suspensions, ointments, creams, transdermal therapeutic systems (eg dressings), milk, pastes, foams, spray powders, implants or stents .
Oral or parenteral application is preferred, in particular
10 The oral application.
The compounds according to the invention can be converted into the application forms already mentioned. This can be done in one way. properly known for mixing with pharmaceutical excipients.
- suitable, inert, non-toxic.
These excipients include, among others, carriers (for example, microcrystalline cellulose, lactose, mannitol), solvents (eg liquid polyethylene glycol), emulsifiers and dispersants.
"sizing agents or humectants (eg sodium dodecyl sulfate, polyoxysorbitane oil), binders (eg polyvinylpyrrolidone), synthetic and natural polymers (eg albumin), stabilizers (eg antioxidants)
20 (eg ascorbic acid), dyes (eg inorganic pigments, such as iron oxide) and flavorings and / or odor correctors.
In general it has been found to be advantageous, in the case of parenteral administration, to administer amounts of approximately 0.001 to 1 mg / kg, preferably approximately 0.01 to 0.5 mg / kg, of body weight
25 to obtain effective results.
In oral application the dosage is approximately 0.01 to 100 mg / kg, preferably approximately 0.01 to 20 mg / kg, and most particularly preferably 0.1 to 10 mglkg of body weight.
However, it may be necessary, if appropriate, to differ from
30 amounts established, specifically as a function of body weight, route of administration, individual response to the active compound, type of preparation and time and / or interval at which administration occurs.
Like this,
in some cases, it may be sufficient to deal with a quantity less than the minimum mentioned above, while in other cases the upper limit mentioned must be exceeded.
In the case of administering larger quantities, it may be advisable to divide them into several domains.
5 individual sessions during the day.
The following implementation examples illustrate the invention.
The invention is not limited to the examples.
The percentages in the tests and examples that follow are, unless otherwise stated, percentages by weight; parts are 10 parts by weight.
Solvent percentages, dilution percentages and concentration data for liquid / liquid solutions are based on volume, respectively. * A.
Examples
. Abbreviations and ac, rô, n, i, m, o, s :,
. aq. aqueous calc solution. calculated
"br s broad singlet (in NMR) DCl direct chemical ionization (in MS) dec. decomposition point DMF dimethylformamide DMSO dimethyl sulfoxide DSC dynamic differential calorimetry equivalent (s) ESl electroborrifor ionization (in MS)
Ethyl gef. observed hour (s) HPLC high performance high pressure liquid chromatography HRMS conc. high resolution mass spec. LC-MS concentrate mass spectrometry coupled to liquid chromatography L1HMDS lithium hexamethyldisilazide
37/66
Me methyl min minute (s) MS mass spectrometry NMR magnetic resonance spectrometry Pd2dba3 tris (dibenzylidenoacetone) dipaladium Ph phenyl PLM powdered light microscope RT arribient temperature Rt retention time (in HPLC) TGA thermogravimetric analysis THF tetrahydrofuran UV spectrometry ultraviolet V / V volume volume ratio (of a solution)
LClMS processes: * Process 1: MS instrument type: Waters ZQ: device type
"HPLC son: Agiient 1100 series; UV DAD; column: Thermo Hypersil GOLD 3 µ 20 mnj x 4 mm; mobile phase A: 1 I of water + 0.5 ml of 50% formic acid,
mobile phase B: 1 I of acetonitrile + 0.5 ml of 50% formic acid; gradient: 0.0min100 ° / jA ~ 3.0min10% A ~ 4.0min10 ° / oA ~ 4.1min100 ° /) A (flow rate 2.5 ml / min); oven: 55 ° C; flow rate: 2 ml / min;
UV detection: 210 nm.
Process 2: Instrument: Waters ACQUITY SQD UPLC Sys-
l has it; column: Waters AcqLIity UPLC HSS T3 1.8 µ 50 x 1 mm; mobile phase A: 1 I of water + 0.25 ml of 99% formic acid, mobile phase B: 1 I of acetonitrile + 0.25 ml of 99% formic acid; gradient: 0.0 min 90% A ~ 1.2 min 5% A ~ 2.0 min 5 ° / 0 In the oven: 50 ° C; flow rate: 0.40 ml / min; UV detection: 210 - 400 nm.
Process 3: Instrument: Micromass Quattro Premier with UPLC Acquity Waiters; column: Thermo Hypersil GOLD 1.9 µ 50 mm x 1 mm; mobile phase A: 1 I of water + 0.5 ml of 50% formic acid, mobile phase B: 1 I of acetonitrile + 0.5 ml of 50% formic acid; gradient: 0.0 min 90 ° 6 A
~ 0.1 min 90 ° 6 A ~ 1.5 min 10 ° / 0 A ~ 2.2 min 10 ° / 0 A; oven 50 ° C; flow rate: 0.33 ml / min; UV detection: 210 nm.
General Processes: PLM: Polarized light microscopy was performed with a particle size system by Clemex PS3 polarized light microscope with a Leica DM microscope equipped with 50X, 100X, 20OX, and 50OX lenses, a monochrome digital camera high resolution 160OX1200 pixel and a motorized XY Marzhauser station (controlled by a Clemex ST-2000 controller). The crystalline material samples were 10 measured on a glass slide (76X26 mm) in an oil drop, and the sample was covered with a glass cover (22X40 mm). DSC: Dynamic differential calorimetry was used to determine the melting points.
The determination was made using
. if a Mettler-Toledo 823 'DSC instrument, equipped with an a-1S robot shows TSO801RO and STAR software'. About 1.5 to 3 mg of the sample was weighed in a small aluminum pan, and closed with the lids
"perforated.
The heat flow was measured in a temperature range of 30 to 400 ° C at a heating rate of 10 ° C / min and under an argon flow of 30 ml / min. 20 TGA: Thermogravimetric analysis was performed with a Mett1er-To | edo TGA / SDTA851 'TGA device supplied with a TSO801RO sample robot and STAR "software. About 1.5 to 3 mg of the sample was weighed in a small pan open aluminum (100 µ1) The weight of the sample was measured in a temperature range of 30 to 400 ° C at a heating rate of 10 ° C / min and under an argon flow of 30 ml / min.
Elementary analyzes were carried out according to methods known to the specialist in accordance with the industrial standard DIN-ISO 17025 of Currenta GmbH & Co.
Starting materials and intermediates: Example 1A 2,6-dichloro-5-fluoricotinamide
C1NCI Fi ~~ NH,
O A suspension of 25 g (130.90 mmol) of 2,6-dichloro-5-fluorine-3-cyanopyridine in conc. (125 ml) was stirred at 60-65 ° C for 1 h. After cooling to RT, the contents of the flask were poured into cold water and extracted three times with acetic acid ethylester (100 ml each time).
The combined organic phases were washed with water (100 ml) and then with aqueous sodium hydrogen carbonate solution (100 ml), dried and concentrated on a rotary evaporator. The material obtained was dried in vacuo. Yield: 24.5 g (90% of theory) 'H NMR (400 MHz, DMSO-d6): 6 = 7.95 (br S, IH), 8.11 (br S, IH), 8.24 ( d, IH). f Example 2A 2-chloro-5-fluoricotinamide jNCl, "'2
To a suspension of 21.9 g (335.35 mmol) of zinc in methanol (207 ml) was added 44 g (210.58 mmol) of 2,6-dichloro-5-fluoricotinamide to the RT. Then acetic acid (18.5 ml) was added, and heated with stirring under reflux for 24 h. After that the contents of the flask were decanted from zinc and ethyl acetate (ethyl acetate) (414 ml) was added as well as a saturated aqueous sodium hydrogen carbonate solution (414 ml), and the mixture was stirred vigorously. Subsequently, it was suction filtered through silica gel and subsequently washed three times with acetic acid ethyl ester (ethyl acetate) (517 ml each time). The organic phase was separated and the aqueous phase was washed with ethyl acetate (258 ml). The combined organic phases were washed once with saturated aqueous sodium hydrogen carbonate solution (414 ml), dried and concentrated
#### ### # ## # # ### # #, # ## # #### ## # ### # # ### # ### # # # ### # ## # ### ###
job: 198 Date: 11/23/2012 Time: 1:45:10 pm under reduced pressure. The crystals thus obtained were reacted with dichloromethane (388 ml) and stirred for 20 min. The mixture was again filtered with suction, and post-washed with diethyl ether and aspirated dry. Yield: 20.2 g (53% of theory) 5 'H NMR (400 MHZ, DMSO-d6): Õ = 7.87 (br S, IH), 7.99 (dd, IH), 8.1O ( brs, 1H), 8.52 (d, 1H). Example 3A 2-chloro-5-fluoricotinonitrile INC | A suspension of 46.2 g (264.66 mmol) of 2-chloro-5-10 fluoricotinamide in dichloromethane (783 ml) was reacted with 81.2 ml (582.25
W mmol) of triethylamine and cooled to 0 ° C. 41.12 * ml (291.13 mmol) of trifluoroacetic anhydride was then dripped slowly, and the mixture was stirred. at 0 ° C for 1.5 h. The reaction solution was subsequently washed twice with saturated aqueous sodium hydrogen carbonate solution 15 (391 ml each time), dried and concentrated under reduced pressure. Yield: 42.1 g (90 ° 6 of theory) 1 H NMR (400 MHZ, DMSO-d6): δ = 8.66 (dd, IH), 8.82 (d, IH). Example 4A 5múor-1H-pjrazo | o [3,4-b] pyridine-3-amine, now: Ú NH, 20 A suspension of 38.5 g (245.93 mmol) of 2-chloro-5 was introduced fluoricotinonitrile in 1,2-ethanediol (380 ml), and then reacted with hydrazine hydrate (119.6 ml, 2.459 mol). It was heated under stirring for 4 h under reflux. During cooling the product precipitated. The yellow crystals were reacted with water (380 ml) and stirred for 10 minutes at RT. Then, the suspension was filtered by suction on a frit, then washed with water (200 ml) and THF (200 ml) at -10 ° C.
The residue was dried under high vacuum in phosphorus pentoxide.
Yield: 22.8 g (61 ° 6 of theory) 'H NMR (400 MHZ, DMSO-d6): Õ = 5.54 (S, 2H), 7.96 (dd, IH),
5 8.38 (m, IH), 12.07 (m, IH). Example 5A 5-fluoro-3-iodo-1H-pyrazolo [3,4-b] pyridine
IN ~ N, H
') "' [5-fluorine-1H- 10 g (65.75 mmol) was introduced into THF (329 ml)." pyrazolo [3,4-b] pyridine-3-amine and cooled to O ° C.
Then 1 "0 was slowly added 16.65 ml (131.46 mmol) of the boron diethyl ether-trifluoride complex. The reaction mixture was further cooled to -10 ° C.
After that a-. A solution of 10.01 g (85.45 mmol) of isopentyl nitride in THF (24.39 ml) was slowly added, and the mixture was subsequently stirred for another 30 min.
The mixture was diluted with cold diethyl ether (329 ml) and the resulting solid was filtered.
The diazonium salt thus prepared was added in portions in a cold solution (0 ° C) of 12.81 g (85.45 mmol) of sodium iodide in acetone (329 ml), and the mixture was stirred at RT for 30 minutes. min.
The reaction mixture was placed in cold water (1.8 l) and extracted twice with acetic acid ethyl ester (ethyl acetate) (487 ml each time). The combined organic phases 20 were washed with saturated aqueous sodium chloride solution (244 ml), dried, filtered and concentrated.
12.1 g (86% purity, 60% of theory) of the desired compound were obtained as a brown solid.
The crude product was reacted without further purification.
LC-MS (process 1): Tr = 1.68 min; MS (ESlpos): m / z = 264 25 (M "H)". Example 6A 5Múor-1- (2Auorbenzyl) -3-iodo-1 H-pyrazolo [3,4-b] pyridMa
, 141 g (462.11 mmol) of the compound of Example 5A was introduced in DMF (2538 ml) of the compound of Example 5A and then 96.09 g (508.32 mmol) of 2-fluorbenzyl bromide was added and 165.62 g (508.32 mmol) of cesium carbonate. The mixture was stirred for two hours at RT. Then the reaction mixture was poured into saturated aqueous sodium chloride solution (13670 ml) and extracted twice with ethyl acetate (5858 ml). The combined organic phases were washed with saturated aqueous sodium chloride solution (3905 ml), dried, filtered and concentrated. The residue was chromatographed.
W · fado on silica gel (mobile phase: petroleum ether 97: 3 ethyl acetate) and the 10 fractions of the product were concentrated. The resulting solid was dissolved in
The dichloromethane is washed once with saturated aqueous thiosulfate solution. sodium (500 ml). It was concentrated to dryness and the residue was suspended in diethyl ether, isolated by suction filtration and dried under high vacuum. 106.6 g (62% of theory) of the desired compound were obtained. 15 'H NMR (400 MHZ, DMSO-d6): i5 = 5.73 (s, 2H), 7.13 - 7.26 (m, 3H), 7.33 - 7.41 (m, IH), 7.94 (dd, IH), 8.69 - 8.73 (m, IH). Example 7A 2- [5-¶úor-1- (2-¶uorbenziI) -1Id-pyrazolo [3,4-b] pyridin-3-yl] -5-nitropihmidine-4,6-diamine T
F, ÀJ) 'Nf' _ NH, H, N " NO,
Introduced in 1,4-dioxane (86 ml) 860 mg (2.32 mmol) of the compound of Example 6A under argon, and the reaction mixture was rinsed with argon for 10 min. Then 3.51 ml (6.95 mmol) of hexabutyld tin and 483 mg (2.55 mmol) of 2-chloro-5-nitropyrimidine-4,6-5 diamine (prepared by the He / vetica Chimica process) Acta (1951), 34, 835-40). Subsequently, 860 mg (0.744 mmol) of tetra-cis (triphenylphosphine) palladium (0) was added and the reaction mixture was heated overnight to reflux. Then it was cooled to RT, reacted with water and extracted twice with acetic acid ethylester (ethyl acetate). The combined organic phases were dried over sodium sulfate, filtered and concentrated. The residue was stirred, the solid was filtered and dried under high vacuum. 355 mg (62% purity, 24% of theory) of the desired compound were obtained. The & - crude product was reacted without further purification.
W "LC-MS (process 2): Tr = 1.03 min
1.5 MS (ESlpos): m / z = 399 (M "H)" Example 8A at 5múor-1- (2-fluorbenzi |) -1H-pyraz | o {3,4-b] pyridine-3-carbonitri | af , J3
N A suspension of 16.03 g (43.19 mmol) of 5-fluorine-1- (2- ¶uorbenzyl) -3-iodo-1H-pyrazolo [3,4-b] pyridine (Example 6A) and 4, 25 g (47.51 20 mmol) of copper cyanide was introduced into DMSO (120 ml) and stirred at 150 ° C for 2 h. After cooling, the contents of the flask were cooled to about 40 ° C and sieved in a solution of concentrated aqueous ammonia (90 ml) and water (500 ml), ethyl acetate (200 ml), reacted with ethyl acetate (acetate) ethyl alcohol) (200 ml) and briefly stirred. The aqueous a-25 phase was separated and extracted two more times with ethyl acetate
(200 ml each time). The combined organic phases were washed twice with 10 ° 6 aqueous sodium chloride solution (100 ml each time), dried and concentrated in vacuo. The crude product was reacted without further purification. Yield: 11.1 g (91 ° 6 of theory) 'H NMR (400 MHZ, DMSO-d6): δ = 5.87 (S, 2H), 7.17 - 7.42 (m, 4H), 8 , 52 (dd, IH), 8.87 (dd, IH). Example 9A 5-Fluorine-1- (2-fluorbenzyl) -1H-pyrazolo [3,4-b] pyridine-3-carboxyimidamide acetate
F, ° ° HN ^ NH, X CH, COOH 2.22 g (41.07 mmol) of sodium methoxide in methanol (270 ml) 11.1 g (41.07 mmol) of 5-fluorine were added -1- (2-fluorbenzyl) -1H-pyrazolo [3,4-b] pyridine-3-carbonitrile (Example 8A), and stirred for 2 h at RT. Then 2.64 g (49.29 mmol) of ammonium chloride and acetic acid (9.17 ml) were added and heated overnight under reflux. Then it was concentrated to dryness, and the residue was extracted in water (100 ml) and ethyl acetate (ethyl acetate) (100 ml) and adjusted to pH 10 with a 2N sodium hydroxide solution watery. It was stirred intensely for about 1 hour at RT. The obtained suspension was filtered with suction and again post washed with ethyl acetate (ethyl acetate (100 ml), with water (100 ml) and again with ethyl acetate (ethyl acetate) (100 ml) The residue was dried in phosphorus pentoxide under vacuum Yield: 9.6 g (78% of theory) MS (ESlpos): m / z = 288 (M "H)" 'H NMR (400 MHZ, DMSO- d6): ô = 1.85 (s, 3H), 5.80 (s, 2H), 7.14 - 7.25 (m, 3H), 7.36 (m, IH), 8.42 (dd , IH), 8.72 (dd, IH).
Example IOA 2- [5-fluoro-1- (2-fluorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-3-yl] -5 - [(E) - phenyldiazenyl] pyrimidineA, 6-diamine F ,, CC 'r'_ H, N "Jq NH,
N ~~ Water (40 ml) and "5 conc. Hydrochloric acid (7.07 ml), 3.85 g (41.34 mmol) of aniline were added with stirring and cooled to 0 ° C. then it was dripped into a solution of 2.85 g (41.34 mmol) of sodium nitride in water (21 ml) between 0 ° C and 5 ° C, and subsequently stirred for 15 ml. - nutes at O ° C. After that, a solution of 4.28 g (52.25 mmol) of sodium acetate in water (19 ml) was dripped quickly at O ° C and then dripped if under good stirring a solution of 2.73 g (41.34 mmol) of malononitrile in ethanol (10 ml), after 2 h at 0 ° C, the precipitate which originated was aspirated and washed three times with water (50 ml each time) and with petroleum ether (50 ml). The still moist residue was dissolved in DMF (46 rt) and added dropwise at precisely 85 "C to a solution of 9.5 g (33.07 mmol) of acetate 15 5múor-1- (2-f | uorbenzi |) -1H-pyraz | o [3,4-b] pyridine-3-carboxyimidamide (E-example 9A) in DMF (46 ml) and triethylamine (5.76 ml) . Then it was stirred at 100 ° C for 4 h and allowed to cool overnight at RT. The mixture was poured into water (480 ml) and stirred for 1 h at RT. After aspiration of the precipitate, it was later washed twice with water (100 ml every 20 times) and twice with methanol (50 ml each time) and then dried under high vacuum. Yield: 9.6 g (59% of theory) LC-MS (process 2): Tr = 1.21 min
MS (ESIpos): m / z = 458 (M "H)" Example 11A 2- [5múor-1- (2-f | uorbenzi |) -1H-pyraz | o [3,4-b] pyridin-3- i |] pyrimjdin-4,5,6-triamine
F) == , í ':: "r' H, N" _ NH, NH, 5 V, a, ri, a, n, te, A,: _ Preparation starting from Example 7A: ^ l was introduced in pyridine (30 ml), 378 mg (0.949 mmol) of the com-. from Example 7A and then 143 mg (0.135 mmol) of palladium (10'6 on carbon) was added. The mixture was hydrogenated overnight at RT under normal hydrogen pressure. The suspension was then filtered through 1 €) diatomaceous earth and the filtered cake was subsequently washed with ethanol. The filtered product was concentrated and yielded 233 mg (81 ° 6 of purity, 51% of theory) of the desired compound, which was reacted without further purification. Variant B: Preparation from Example IOA: 39.23 g (85.75 mmol) of the compound of Example IOA was introduced into DMF (800 ml) and then added to 4 g of palladium (10 % in carbon). The mixture was hydrogenated with stirring overnight under normal pressure of hydrogen. The preparation was filtered on diatomaceous earth and with little DMF and thereafter washed with little methanol and concentrated until drying. The residue was reacted with 20 acetic acid ethylester (ethyl acetate) and strongly agitated, the precipitate was aspirated, then washed with acetic acid ethylester (ethyl acetate) and diisopropylether and dried under high vacuum with Sicapent. Yield: 31.7 g (100% of theory) LC-MS (process 2): Tr = 0.78 min 25 MS (ESIpos): m / z = 369 (M "H)"
Example of execution: Example 1: {4,6-diamino-2- [5-fluoro-1- (2-fluorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin-5- il} methyl carbamate F ) ==
IN ~ h,, i! -1 / "'
N "" "V H2N> Ç, H, The "CH,
.5 In pyridine (600 ml), 31.75 g (86.20 mmol) of the compound of example 11A was introduced under argon and cooled to 0 ° C.
So add
· A solution of 6.66 ml (86.20 mmol) of methyl chloroform in dichloromethane (10 ml) was added dropwise and the mixture was stirred at 0 ° C for 1 hour.
Then the reaction mixture was brought to RT (room temperature), concentrated under reduced pressure and codistilled repeatedly with toluene.
The residue was stirred with water / ethanol and then filtered on a frit, after which it was washed with ethanol and ethyl acetate.
Subsequently. the residue was again stirred with diethyl ether, isolated by suction filtration and then dried under a high vacuum.
Yield: 24.24 g (65 ° /) of theory) LC-MS (process 2): Tr = 0.79 minutes MS (ESlpos): m / z = 427 (M "H)" 'H NMR (400 MHZ , DMSO-d6): 15 = 3.62 (br.
S, 3H), 5.79 (S, 2H), 6.22 (br.
S, 4H), 7.10 - 7.19 (m, 2H), 7.19 - 7.26 (m, IH), 7.32 - 7.40 (m, 1H), 7.67e7.99 ( 2br.s, 1H), 8.66 (m, 1H), 8.89 (dd, 1H). Example 2: {4,6-diamino-2- [5-fluorine-1- (2-¶uorbenzyl) -1 H-pyraz | o [3,4-b] pirjdjn-
3-yl] pyrimidin-5-yl} methyl methylcarbamate Fr ~~ "
F £ y: , V "'" H, N) 1 ::, H3C Q — CH, An amount of 200 mg (0.469 mmol) of 4,6-diamino-2- [5- "fluorine-1 - (2-fluorbenzyl) -1 H-pyraz | o [3,4-b] pjridin-3-i |] pyrimidin-5-j | carbamate (example 1) was introduced into THF (5 ml) at O ° C. Then 0.704 ml, 5 (0.704 mmol) of lithium hexamethyldisilazane solution (IM in THF) was added and the mixture was stirred at that temperature for 20 minutes. Subsequently, 43.8 µ1 (0.704 mmol) of iodomethane were added and the mixture was heated to RT. After 1 hour at this temperature, the reaction was interrupted with water (1 ml) and the reaction mixture was concentrated, residue 10 being separated by means of preparatory RP-HPLC (water gradient (+ formic acid 0 , 05 ° / j) -acetonitri | a). Yield: 90 mg (44% of theory) LC-MS (process 2): Tr = 0.85 minutes MS (ESlpos): m / z = 441 (M "H)" 15 'H NMR (400 MHz, DMSO- d6): i5 = 3.00 (s, 3H), 3.53 and 3.66 (2s, 3H), 5.81 (s, 2H), 6.57 (br. s, 4H), 7.13 (m, 2H), 7.22 (m, IH), 7.35 (m, IH), 8.67 (m, IH), 8.87 (dd, IH). Example 3: {4,6-diamino-2- [5-f | uor-1- (2-¶uorbenzi |) -1H-pyraz | o [3,4-b] pirjdin- 20 3-i |] pirjmidin -5-i |} (2,2,2-trifluorethi |) methyl carbamate
,,, jt 'H, N "jjj - ,,, , _ÇO FkF °" cH, An amount of 3.470 g (8.138 mmol) of the compound of e-. Example 1 was suspended in 35 ml of THF, mixed by adding 358 - mg (8.952 mmol) of sodium hydride (60% suspension in mineral oil) to O "C and stirred at 0 ° C for 90 minutes during a solution was formed A quantity of 2.519 g (8.952 mmol) of 2,2,2- "trifluorethyl trichloromethanesulfonate was added and the mixture was stirred at RT for 48 hours. It was then stirred with water and concentrated on a rotary evaporator. The residue was absorbed in ethyl acetate, and the organic phase was washed twice with water and dried over sodium sulfate. This provided 5.005 g of the 10 target compound (79% of theory, 65% HPLC purity). A quantity of 250 mg of the residue was purified by means of preparatory HPLC (mobile phase: methanol / water, gradient 30:70 ~ 90:10). , LC-MS (process 2): Tr = 0.97 minutes; MS (Elpos): m / z = 509 (M + H) ".
15 'H NMR (400 MHZ, DMSO-d6): 8 jppm] = 3.63 (S, 3H), 4.06-4.15 (m, 2H), 5.80 (S, 2H), 6, 46 (br S, 4H) 7.11-7.15 (m, 2H), 7.20-7.25 (m, IH), 7.33-7.38 (m, IH), 8.66 ( dd, IH), 8.91 (dd, IH). Example 4: {4,6-diamino-2- [5-f | uor-1- (2-f] uorbenzj |) -1H-pyraz | o [3,4-b] pyridin-20 3-yl] pyrimidin -5-yl} carbamate methyl hydrochloride
ÁJ ^ N '\ _ /) "NH,"' 2— (° X HCl O "CH, A solution of 100 mg (0.235 mmol) of example 1 in 2 ml of. 1,4-dioxane was prepared in a 5 ml brown glass bottle. 2 ml of isopropane! and 235 µ1 (0.235 mmol) of 1M hydrochloric acid were successively added to this solution, and the solution was stirred at RT until the solvent "5, evaporated Air drying provided 102 mg (94% of theory) of the title compound.
W PLM (100x): crystalline DSC: 224 ° C (dec., AH = 189 J / g) TGA: weight loss i '/ o at 80 "C 10 LC-MS (process 3): Tr = 0, 91 minute MS (ESlpos): m / z = 427 (M + H) "'H NMR (400 MHZ, DMSO-d6): õ [pm] = 3.35 and 3.65 (2 s, 3H), 5 , 92 (s, 2H), 7.15 (dd, IH), 7.25 (m, 2H), 7.37 (m, IH), 7.75 (br s, 4H), 8.08 e8, 39 (2s, 1H), 8.82 (m, 2H), 13.2 (brs, 1H).
15 Elemental analysis for C19H16F2N8O2 + HCl: calculated: ° / oC 49.31; % H 3.70; % N 24.21; observed: ° / oC 49.5; % H 3.7; % N 24.3. Example 5: {4,6-diamino-2- [5-f | uor-1- (2-¶uorbenzi |) -1H-pyraz | o [3,4-b] pyridin-20 3-yl] pyrimidin- 5-yl} carbamate methyl sulfate
F) " I '~ n, F") "' ^ N 7 ~ /)" NH, XH, SO, "'! - {° O" CH, A 100 mg (0.235 mmol) solution of example 1 in 2 ml of 1,4-dioxane was prepared in a 5 ml brown glass bottle. Add. 2 ml of isopropanol and a solution of 938 µ1 (0.235 - mmol) of 0.25 M sulfuric acid were successively added to this solution, and the solution was stirred at RT
G -5 until the solvent has evaporated. Air drying provided 103 mg (83.7 ° 6 of theory) of the title compound. 0 PLM (100x): crystalline DSC: 242 ° C (dec., AH = 115 J / g) TGA: no weight loss before a decomposition 10 LC-MS (process 3): Tr = 0.91 min MS ( ESlpos): m / z = 427 (M "H)" 'H NMR (400 MHZ, DMSO-d6): ô [pm] = 3.56 and 3.66 (2 s, 3H), 5.93 (s , 2H), 7.16 (m, 2H), 7.25 (dd, IH), 7.38 (m, IH), 7.59 (br s, 4H), 8.03 and 8.32 (2s, 1H), 8.82 (m, 2Fl), 13.0 (brs, 1H).
15 Elemental analysis for C19H16F2N8O2 + H2SO4: calculated: ° / oC 43.51; % H 3.46; % N 21.37; observed: ° / oC 43.6; % H 3.4; % N 21.2.
Example 6: {4,6-diamino-2-I5-núor-1- (2-¶uorbenzi |) -1H-pyraz | o [3,4-b] pyridin-20 3-yl] pyrimidin-5-yl } methyl phosphate carbamate
,, J '~ NN ~ /) "NH," " § -C ° XH, PO, O" CH, A solution of 100 mg (0.235 mmol) of example 1 in 2 ml of 1,4-dioxane was prepared in a 5 ml brown glass bottle. Add-
2 ml of THF and a solution of 16 µ1 (0.235 mmol) of 85% phosphoric acid in 0.3 ml of water were successively given to that solution, and the solution was stirred at RT until the solvent had evaporated. . Air drying provided 105 mg (85.4% of theory) of the title compound.
W PLM (100x): crystalline DSC: 183 ° C (dec., AH = 65 J / g) TGA: 6 ° / 0 of weight loss before a decomposition 10 LC-MS (process 3): Tr = 0, 91 minute MS (ESlpos): ià / Z = 427 (M + H) "'H NMR (400 MHz, DMSO-d6): ô [pm] = 3.57 and 3.62 (2 s, superimposed methyl signal by the water signal, 3H), 5.79 (s, 2H), 6.22 (br s, 4H), 7.15 (m, 2H), 7.22 (dd, IH), 7.36 (m , IH), 7.67 and 7.99 (2 S, IH), 8.66 (m, 15 IH), 8.90 (m, IH). "P-NMR (400 MHZ, DMSO-d6): i5 jppm] = -1.1 Elemental analysis for C19H16F2N8O2 + H3PO4 + 2 H2O: calculated: 40.72 ° / oC; % H 4.14; % N 19.99; note: ° / oC 40.5; % H 4.0; % N 19.5. 20 Example 7: {4,6-diamjno-2- [5-f | uor-1- (2-f | uorbenzi |) -1H-pyraz | o (3,4-b] pyridin-3-yl] pyrimidin -5-yl} methyl mesylate carbamate
F t "" r ~ ij ~ 9 / = "N \, /)" NH, H2N # Yo X H3CSO, HO "CH, A solution of 100 mg (0.235 mmol) of example 1 in 2 ml of 1 , 4-dioxane was prepared in a 25 ml brown glass bottle, 2 ml of ethanol and a solution of 22.5 mg (0.235 - mmol) of methanesulfonic acid in 0.3 ml of water were successively added to that solution, and the .5 solution was stirred at RT until the solvent had evaporated. Air drying provided 103 mg (84 ° 6 of theory) of the title compound.
P PLM (100x): crystalline DSC: 154 ° C (AH = 11.7 J / g), 167 ° C (AH = -5 J / g), 215.2 ° C (dec, AH = 56.1 J / g) 10 TGA: gradual weight loss during LC-MS measurement (process 3): Tr = 0.91 minutes MS (ESIpos): m / z = 427 (M "H)" 'H NMR (400 MHz, DMSO-d6): õ [pm] = 2.31 (s, 3H), 3.57 and 3.66 (2 s, 3H), 5.93 (s, 2H), 7.17 (m, 2H) , 7.25 (dd, IH), 7.39 (m, IH), 7.66 (s 15 br, 4H), 8.06e8.34 (2s, 1H), 8.81 (dd, 1H), 8.83 (s, 1H), 13.0 (brs, 1H). Elemental analysis for C19H16F2N8O2 + CH4O3S + H2O: calculated: ° /, C 44.44; % H 4.14; % N 20.7; observed: ° / oC 44.3; 6H 4.1; % N 20.2. Example 8: 20 {4,6-diamino-2- [5-fluoro-1- (2-fluorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-3-j |] pyrimidin-5-i | } methyl ethane-1,2-disulfonate carbamate
FF / J h: C3 € oh '\, /) "NH,"' fc ° O "CH, A solution of 100 mg (0.235 mmol) of example 1 in 2 ml of 1,4-dioxane was prepared in a 25 ml brown glass bottle 2 ml of isopropanol and 44.6 mg (0.235 mmol) of ethane-1,2-disulfonic acid were successively added to this solution, and the solution was stirred at RT until the solvent has evaporated. Air drying provided 111 mg (73.7 ° 6 of theory) of the title compound.
P PLM (100x): predominantly crystalline DSC: 97 ° C (dec., AH = 103 J / g) TGA: gradual weight loss during measurement 10 LC-MS (process 3): Tr = 0.90 minute MS ( ESlpos): m / z = 427 (M "H)" 'H NMR (400 MHZ, DMSO-dQ: ô [pm] = 2.66 (s, 4H), 3.57 and 3.66 (2 s, methyl signal superimposed by the water signal, 3H), 5.93 (s, 2H), 7.17 (m, 2H), 7.25 (m, IH), 7.39 (m, IH), 8, 05 and 8.35 (2 s, IH), 8.80 (dd, 15 1H), 8.84 (s, IH). Elemental analysis for C19H16F2NbO2 "C2H6O6S2 + 0.25 H2O + 0.25 C4H8O2: calculated: ° / qC 41.09;% H 3.84;% N 17.42; note: ° / oC 41.2;% H 4.2;% N 17.6. 2Ò Example 9: {4,6-diamino -2- [5-fluoro-1- (2-¶uorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin-5-yl} carbamate methyl maleate F
ÁJí,: 'N lm 7 , /) "NH,' ° _ {°} _ ° '°"' K- {° O "CH,
A solution of 100 mg (0.235 mmol) of Example 1 in 2 ml of 1,4-dioxane was prepared in a 25 ml brown glass bottle.
Adi-. 2 ml of isopropanol and 27.2 mg (0.235 mmol) of
· Maleic acid to that solution, and the solution was stirred at RT until the solution evaporated.
Air drying provided 108 mg (84.9% of theory) of the title compound.
PLM (100x): crystalline DSC: 192 ° C (dec., AH = 173 J / g) TGA: 3 ° 6 of weight loss before a decomposition 10 LC-MS (process 3): Tr = 0.91 minutes MS (EStpos): m / z = 427 (M + H) "'H NMR (400 MHZ, DMSO-dQ: Ô [pm] = 3.56 and 3.64 (2 S, superseded by the dioxane signal , 3H), 5.85 (s, 2H), 6.16 (s, 2H), 6.9 (br s, 4H), 7.15 (m, 2H), 7.23 (dd, 1H), 7.37 (m, 1H), 7.85e8.13 (2 S, IH), 8.73 (S, 1H),
15 8.86 (dd, 1H). Elemental analysis for C19H16F2N8O2 + C4H4O4 + 0.5 H2O + 0.5 C4H8O2: calculated: ° / oC 50.42; % H 4.23; % N 18.82; observed: ° / oC 50.7; ° / oH 3.9; % N 18.8. 20 Example 10: {4,6Diamino-2- [5-f | uor-1- (2-f | uorbenzi |) -1H-pjrazo | o [3,4-b] pyridin-3-yl] pyrimidin -5-yl} methyl nitrate carbamate
F, = "^ NN \ _ /)" NH, "HNO," ' he ° O "CH, A solution of 100 mg (0.235 mmol) of example 1 in 2 ml of isopropanol was prepared in a glass bottle 25 ml brown, 2 ml of isopropanol and 0.235 µ1 (0.235 mmol) of 1M nitric acid were successively added to this solution, and the solution was stirred at RT until the solvent evaporated. Air drying provided 103 mg (89.7 ° 6 of theory) of the title compound PLM (100x): DSC crystalline: 175 ° C (dec., AH = -224 j / g) TGA: 3 ° / 0 of weight loss before decomposition 10 LC-MS (process 3): Tr = 0.91 minutes MS (ESlpos): m / z = 427 (M "H)" 'H NMR (400 MHZ, DMSO-d6): 6 [pm] = 3.57 and 3.66 (2 S, 3H), 5.93 (S, 2H), 7.16 (m, 2H), 7.25 (dd, IH), 7.38 ( m, IH), 7.65 (br s, 4H), 8.02 and 8.32 (2s, 1H), 8.80 (dd, 1H), 8.83 (S, 1H), 13.0 (brs , 1H).
15 Elemental analysis for C19H16F2N8O2 + HNO3 + 0.75 H2O: calculated: ° / oC 45.38; ° 6H 3.71; % N 25.07; observed: ° / oC 45.4; ° 6H 3.7; % N 25.0. B. Av, a, l, i, actionA pharmacological efficacy The pharmacological effect of the compounds according to the invention can be demonstrated in the following tests: B-l. Vasorelaxing effect in vitro Rabbits are numb by a blow to the neck and
swimming.
The aorta is removed, freed from adherent tissue and divided into 1.5 mm wide rings.
The rings are individually placed under an initial tension in 5 ml organ baths with Krebs-Henseleit solution which is at 37 ° C, carbonated with carbon and with the following
5 composition (in each case in mM): sodium chloride: 119: potassium chloride: 4.8; calcium chloride dihydrate: 1; magnesium sulfate heptahydrate: 1.4; potassium dihydrogen phosphate: 1.2; sodium bicarbonate: 25; glucose: 10. The contraction force is detected with Statham UC2 cells, amplified and digitalized via A / D converters (DAS-1802 HC, Keithley
10 lnstruments, Munich) and registered in parallel in a line register.
To generate a contraction, phenylephrine is added to the bath cumulatively in increasing concentration.
After several control cycles, the subs-. substance to be investigated is added to each other dosage pass
- increasing in each case, and the height of the contraction achieved is compared with the height of the contraction achieved in the last preceding passage.
The concentration required to reduce the height of the control value by 50 ° / o
"is calculated from that (value | C50). The standard administration volume is 5 µ1 and the proportion of DMSO in the bath solution corresponds to 0.1%. Representative values | C50 for the compounds according to
20 the invention are shown in the table below (table 1): Ea, b, e, |, a, 1: _
Example NO. [NM]
1 ! 958 2 251 3 515 B-2. Effect on a recombinant cyanide reporter cell line
late cyclase The cellular activity of the compounds according to the invention is
25 determined using a recombinant guanylate cyclase reporter cell line, as described in F.
Wunder et al., Anal.
Biochem. 339, 104-112
(2005). Representative values (MEC = minimum effective concentration)
for the compounds according to the invention are shown in the table below (Table 2): Table 2: Example No. MEC fµM] 1 0.3 2 0.1 3 0.03 B-3. Blood pressure measurement by radiotelemetry in awake, spontaneously hypertensive mice A commercially available telemetry system from DATA SCIENCES INTERNATIONAL DSl, USA, described below, is employed for. blood pressure measurements in awake rats. The system consists of 3 main components: "10 - implantable transmitters (Phy- telemetry transmitter" siotel®) - receivers (Physiotef receiver) that are connected via a
W multiplexer (DSl Data Exchange Matrix) to a - computer for data acquisition. 15 The telemetry equipment makes it possible to continuously record blood pressure, heartbeat and body movement of awakened animals in their usual habitat.
Ma, te, laughs, a, l, a, n, i, m, a, I, The tests are performed on spontaneously hypertensive female adult rats (SHR Okamoto) with a body weight of> 200 g. SHR / NCrl of the Okamoto Kyoto School of Medicine, 1963 were a cross between male Wistar Kyoto rats with very high blood pressure and female rats with a slightly high blood pressure and delivered to the U.S. National Institute of Health at F13.
25 After implantation of the transmitter, the test animals are housed individually in Makrolon type 3 cages. They have free access to standard food and water.
The day / night rhythm in the experimental laboratory is altered by
environment at 6:00 am and 7:00 pm. Implantation of the transmitter The telemetry transmitters employed TA11 PA - C40 are surgically implanted under aseptic conditions in test animals 5 at least 14 days before the first experimental use.
Animals instructed in this way can be used repeatedly after the wounds have healed and the implants are established.
For implantation, fasting animals are anesthetized with pentobarbital (Nembutal, Sanofi: 50 mg / kg i.p.) and shaved and disinfected 10 over a long area of their abdomen.
After opening its abdominal cavity along the linea alba, the system fluid-filled measurement catheter is inserted into the descending aorta towards the skull. above the fork and is fixed with fabric glue (Vet8onO®, 3M). The carcass-
- the trarismis is fixed intraperitoneally to the musculature of the abdominal wall 15, and the wound is closed in layers.
An antibiotic (Tardomyocel COMP, Bayer, 1 ml / kg S.C.) is administered in post-operation for prophylaxis against infection.
Substances and solutions Unless otherwise indicated, the substances to be investigated are administered orally by gavage (pharyngeal tube) in each case to a group of animals (n = 6). The test substances are dissolved in appropriate solvent mixtures, or suspended in 0.5% Tylose, suitable for an administration volume of 5 ml / kg body weight. 25 A group of animals treated with solvent is employed as a control group.
Test procedures The telemetry measuring equipment present is configured for 24 animals.
Each test is registered under a test number (V _ year 30 month day). Each of the live mice instrumented in the facility is assigned a separate receiving antenna (1010 Receiver, DSI).
The implanted transmitters can be activated externally by means of a built-in magnetic switch and are connected for transmission during the test. The emitted signals can be detected online by a data acquisition system (Dataquest® A, R.T. By Windows, 5 DSl) and can be properly processed. The data are stored in each case in a file created for this purpose and which carries the test number. In a standard procedure, the following data are recorded for each 10-second period in each case: 10 - systolic blood pressure (SBP) - diastolic blood pressure (DBP)
H - mean arterial pressure (MAP) - heartbeat (HR) ^ - activity (ACT). 15 The acquisition of measured values is repeated at 5 minute intervals with computer control. The source data obtained as "absolute values" are corrected in the diagram with the measured instantaneous barometric pressure (Ambient Pressure Reference Monitor; APR-I) and are stored as individual data. Further technical details are provided in the extensive documentation of the manufacturer company (DSl). Unless otherwise stated, test substances are administered at 9:00 am on the day of the test. After administration, the parameters described above are measured over 24 hours. Evaluation After completion of the test, the individual recorded data are treated using the analysis software (Dataquest® ART ® Analysis) .The base value here is assumed to be 2 hours prior to q administration of the substance, so that the set of Selected data includes the period from 7:00 am on the day of the test until 9:00 am on the following day The data are rounded over a predeterminable time by determining averages (averages of 15 minutes) and are transferred
as a text file for a storage medium. The measured values thus treated and compressed are transferred to Excel spreadsheets and are tabulated. For each test day, the data obtained is stored in a dedicated file with the test number. The test results and protocols 5 are filed in paper form and classified by number. Representative values for the compounds according to the invention are shown in the table below (Table 3): Table 3: Example 1: Example 2: Vehicle! Dosa- Dosa- Vehicle I Dosa- gem gem l gem | 0.3 3.0 i 0.3 I mg / kg mg / kg I mg / kg p.o. powder. powder.
"I Hours Pressure! Pressure Pressure Hours Pressure I Blood pressure I bloody bloody bloody bloody) after I average administration I average medical average (mm I dia (mm. II traction (mm Hg)); i; ("" day (mm traction of the sub-Hg) substance- Hg) I Hg) tia cia I0 153.6 151.0 149.0 0 149.0 161.3 - -! 1 164.5 148.4 129.3 1 158.2 145.7 I2 146.7 136.4 111.1 2 142.2 130.5 | 3 145.4 130.6 106, 0 3 149.2 121.5 I4 149.6 129.1 107.8 4 152.3 123.1 | 5 149.9 132.8 109.3 5 155.8 121.6 I6 151.6 125.6 106.8 6 147.3 123.8! 7 147.6 131.9 110.9 7 147.3 124.4 - - I8 147.5 131.8 109.8 8 149.3 128.7 | 9 150 , 8 138.5 114.3 9 151.0 133.7! 10 149.8 138.3 114.5 10 152.5 139.2 I "154.0 138.9 115.6 11 150.3 137, 9! "145.3 137.7 118.8 12 146.2 143.0 113 141.1 142.9 120.4 13 143.2 146.0
Example 1: Example 2: Vehicle I Dosa- Dosa- Vehicle I Dosa- gem gem) I 0.3 3.0 i 0.3 I mg / kg mg / kg I mglkg p.o. PeOw p.o.
I Hours Pressure I Pressure Pressure Hours Pressure I Pressure I after blood I blood after blood I blood! median administration I median median me- median median administration day (mm I day (mm (mm Hg)); i; ("" day (mm I traction of the subs-Hg) substance- Hg) I Hg) substance | 14 147.8 144.5 122.8 14 146.4 149.2 —— l 15 151.0 143.8 125.8 15 150.5 152.3 151.3 146.3 131.5 16 145.3 155.5 "I 16 17 148.8 141.8 124.7 17 143.9 156.3 I 18 149.2 138.4 129.6 18 150.3 157, 3 '! 19 151.2 149.2 135.6 19 147.7 156.9 152.6 145.1 135.2 20 153.4 156.3. [20 I 21 146.3 142.1 129.3 21 148.6 149.3! 22 146.3 141.8 128.3 22 153.3 147.1 I 23 150.3 143.6 130.2 23 151.1 153.1 I 24 147.4 135, 1,130.8 24 154.1 152.3 Literature Klaus Witte, Kai Hu, Johanna Swiatek, Claudia Mussig, Georg Ertl and Bjõm Lemmer: Experimental heart failure in rats: effects on cardiovas- cular circadian rhythms and on myocardial j3-adrenergic signaling Cardio- 5 vasc Res 47 (2): 203-405, 2000; Kozo Okamoto: Spontaneous hypertension in rats. Lnt Rev Exp Pathol 7: 227- 270, 1969; Maarten van den Buuse: Circian Rhythms of Blood Pressure, He art Rate, and Locomotor Activity in Spontaneously Hypertensive Rats as Measured With Radio-Telemetry. Physysology & Behavior 55 (4): 783-787, 1994 10 B-4. Determination of pharmacokinetic parameters following intravenous and oral administration: The pharmacokinetic parameters of the substances are determined
male CD-l mice, male Wistar rats and beagle bitches. The administration volume is 10 ml / kg per mouse, 5 ml / kg per rat and 0.5 ml / kg per bitch. Intravenous administration occurs through a specific pIasma formulation of the species IDMSO (99/1) for mice and 5 mice and through water / PEG400 / ethanol (50/40/10) in the case of bitches. For easier blood removal, a silicone catheter is inserted into the vena jugu / aris right extremity of the rats before administration of the substance. The surgical intervention occurs one day before the test with isofluran anesthesia and administration of an analgesic (atropine / rimadil 10 (3/1) 0.1 ml S.C.). The administration of the substance occurs as an i.v. bolus in the case of mice, as an i.v. bolus or via an infusion for 15 minutes in the case of rats and via an infusion for 15 minutes in the case of bitches. A b. blood removal occurs after 0.033, 0.083, 0.17, 0.5, 1, 2, 3, 4, 6, 7 and 24
F hours in the case of mice and, after an infusion for 15 minutes, after 15 0.083, 0.25, 0.28, 0.33, 0.42, 0.75, 1, 2, 3, 4, 6, 7 and 24 hours in case of ca-. them and rats and after an i.v. bolus administration, after 0.033, 0.083, - 0.17, 0.5, 1, 2, 3, 4, 6, 7 and 24 hours in the case of rats. For all species, oral administration of the dissolved substance via pharyngeal tube is performed based on a formulation of water / PEG400 / ethanol (50/40/10).
20 Here, blood is removed from rats and bitches after 0.083, 0.17, 0.5, 0.75, 1, 2, 3, 4, 6, 7 and 24 hours. The blood is removed into tubes with heparin. Blood plasma is then obtained by centrifugation; if necessary, it can be stored at -20 ° C until further processing. An internal standard (ZK 228859) is added to unknown samples, calibration samples and QCs, and protein precipitation occurs in excess of acetonitrile. After adding an ammonium acetate buffer (0.01 M, pH 6.8 (example 1/3) or pH 3.0 (example 2)) and a subsequent vortex, the mixture is centrifuged at 1000 g and the supernatant is examined by LC-MS / MS (APl 4000, AB Sciex). Chromatographic separation is performed on an Agilent 11OO-HPLC. The injection volume is 10 µ1. The separation column used is a Phenomenex Luna 5µ C8 (2) IOOA 50x2mm, adjusted to a temperature of 40 ° C. For example 1, a binary mobile phase with a gradient of 400 µl / min is used (A: ammonium acetate buffer O, O1M with pH 6.8; B: 0.1 ° 6 formic acid in acetonitrile): 0 min ( 90% A), 1 min (90% A), 3.5 min (15% A), 4.5 min (15% A), 4.6 min (90% A), 7 min (90% A) . For example 2, a binary mobile phase with a gradient of 500 µl / min is used instead (A: ammonium acetate buffer O, O1M with pH 3.0; B: 0.1% formic acid in acetonitrile ): 0 min (90 ° 6 A), 1.5 min (90 ° / o A), 3.5 min (10 ° 6 A), 4.5 min (10 ° 6 A), 5 min (90% A), 7 min (90% A). For example 3, a binary mobile solvent at 500 µl / min is used instead (A: ammonium acetate buffer O, O1M with pH 6.8; B: 0.1% formic acid in 10 acetonitrile): 0 min (90 ° 6 A), 1 min (90 ° 6 A), 3 min (10% A), 4 min (10% A), 4.5 min (90 ° 6 A), 6 min (90 ° 6 A) ). The temperature of the Turbo V Ion source is 500 ° C.
The following MS instrument parameters are used: floor gas: 20 units (example 1), 16 units (example 2) or 15 units (for example 3), Ion spray voltage: 5 kV (example 1 / 2) or 4.5 units 15 (example 3), gas 1 35 units (example 1/3) or 25 units (example 2), gas 2 30 units, CAD gas 4 units (example 1/3) or 3 units (example 2). Substances are quantified by peak heights or areas using Ion chromatograms extracted from specific MRM tests. The plasma concentration curves determined in time are used to calculate pharmacokinetic parameters, such as AUC, Cm ,,, MRT (mean residence time), t1l2 (half-life) and CL (clearance) using the validated programs for pharmacokinetic calculations KinEx (Vers.
2.5 and 3). Since the quantification of substances occurs in plasma, it is necessary to determine the plasma blood distribution of the substance in order to adjust the pharmacokinetic parameters in an appropriate way. For this purpose, a defined amount of substance is incubated in heparinized whole blood of the species in question in a stirred roller mixer for 20 minutes. After centrifugation at 10000g, the plasma concentration of 30 ma is measured (see above) and is determined by calculating the quotient of the CJCp values. Following the intravenous administration of 0.3 mg / kg of the
according to the invention in rats, the following values were obtained: Example 1. * 2. ** 3. ** AUCno, m, [kg · h / l] 4.36 1.79 1.36 CL blood [lh / kg] _ 0.29 0.53 1.02 MRT [h] 4.1 2.3 2.3 t1 / 2 [h] 3.4 1.7 1.9 * infusion for 15 minutes ** cake administration iv, 5 B-5. SeAuran, ça profile The substances according to the invention show a surprisingly favorable safety profile in vivo, which has been established by non-clinical studies according to the OECD (OECD guidelines for testing of. Chemicals, No. 407) and ICH guidelines (3BS2A) 10 C. Execution examples for pharmaceutical compositions The compounds according to the invention can be converted "into pharmaceutical formulations as follows: Tablets: Composition: 15 100 mg of the compound according to the invention, 50 mg of lactose (monohydrate), 50 mg of corn starch (native), 10 mg of poHvinylpyrrodone (PVP 25) (BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate Weight dokblete 212 mg, diameter 8 mm , radius of ajNahjm 12 mm.
Preparation: The mixture of the compound according to the invention, lactose and starch is granulated with a 5 ° / 0 (w / w) solution of PVP in water. After drying, the granules are mixed with magnesium stearate for 5 minutes. This mixture is pressed with a conventional press to form tablets (for tablet sizes see above). The guide value used for pressing is a pressing force of 15 KN.
Suspension for oral administration: Composition: 1000 mg of the compound according to the invention, 1000 mg of ethanol (96%), 400 mg of Rhodigei® (xanthan gum from FMC, Pennsylvania, 5 USA) and 99 g of water. An individual dose of 100 mg of the compound according to the invention corresponds to 10 ml of oral suspension. Preparation: Rhodigel is suspended in ethanol and the compound according to the invention is added to the suspension. The water is added during stirring. The mixture is stirred for approximately 6 hours until the swelling of Rhodigel has ended. r Solution for oral administration: Composition: «
1.5 500 mg of the compound according to the invention, 2.5 g of polysorbate and 97 g of polyethylene glycol 400. An individual dose of 100 mg of the "compound according to the invention corresponds to 20 g of oral solution. Preparation : The compound according to the invention is suspended in the mixture 20 of polyethylene glycol and polysorbate during stirring The stirring operation is continued until the complete dissolution of the compound according to the invention Solution iv: The compound according to The invention is dissolved in a concentration below the saturation solubility in a physiologically compatible solvent (for example, isotonic saline, glucose solution 5 ° / 0 or solution of PEG 400 3 ° / o). sterile filtration and is filled in sterile injection vials and free of pyrogen.

权利要求:
Claims (11)
[1]
1. Compound of formula (I)
F fjt '' S] lnh, h'no ,, ('yr' d 'o H, C: OZ in which R1 represents hydrogen or (C1-C4) -a | qui1a, "5 where (C1-C4) -a | qui | a can be substituted by one or two substitutants independently of one another selected from the group fluorine and triflu-. ormethyl,
P as well as its N-oxides, salts, solvates, salts of N-oxides and solvates of N-oxides and salts. 10
[2]
A compound of formula (I) according to claim 1, in which R 'represents hydrogen or methyl, where methyl can be replaced by a trifluoromethyl substituent, as well as its salts, solvates and solvates of the salts. A compound of the formula (I) according to claim 1 or 2, selected from the group: {4,6-diamino-2- [5-¶úor-1- (2-fluorbenzyl) -1 H- pyrazolo [3,4-b] pyridin-3- ii] pyrimidin-5-yl} methyl {4,6-diamino-2- [5-¶úor-1- (2-¶uorbenzil) -1 H- pyrazolo [3,4-b] pyridin-20 3-yl] pyrimidin-5-yl} methyl methylcarbamate methyl {4,6-diamino-2- [5-fluoro-1- (2-fluorbenzyl) -1 H- pyrazolo [3,4- b] pyridin-3-i |] pyrimidin-5-i |} (2,2,2-trif | uoretj |) methyl carbamate {4,6-diamino-2- [5-fluorine -1- (2-fluorbenzyl) -1 H-pyrazolo [3,4-b] pyridin-
[3]
3-yl] pyrimidin-5-yl} carbamate methyl hydrochloride {4,6-diamino-2- [5-¶úor-1- (2-¶uorbenzi |) -1H-pirwo | ol3,4-b] pyridin - 3-yl] pyrimidin-5-yl} carbamate methyl sulfate {4,6-d jamino-2- [5múor-1- (2-f | uorbenzyl) -1H-pyraz | o [3,4-b] pirjdin- 5 3-iqpirimidin-5-i |} carbamate methyl phosphate {4,6-diamino-2- [5-f | uor-1- (2-fluorenzenz1) -1H-pyraz | o [3,4- b] pyridin-3-yl] pyrimidin-5-yl} carbamate methyl {4,6-diamino-2- [5-¶úor-1- (2-¶uorbenziI) -1 | q-pirazo | o [ 3,4-b] pjridin-3-yl] pyrimidin-5-yl} carbamate ethane-1,2-disulfonate 10 {4,6-diamino-2- [5-¶úor-1- (2-¶uorbenzil) -1 H-pyrazolo [3,4-b] pyridin-3-yl] pyrimidin-5-yl} carbamate methyl maleate {4,6-diamino-2- [5-fluoro-1- (2-fluorbenzyl) - 1 H-pyrazolo [3,4-b] pyridin-. 3-yl] pyrimidin-5-yl} carbamate methyl nitrate.
W.
[4]
4. Process for preparing compounds of the formula (I), as defined in claims 1 to 3, characterized by the fact that the compound of the formula (ll) F ) == IN ~ h, F "{' l (II) [A] is reacted in an inert solvent in the presence of hexa-butyl tin and an appropriate palladium catalyst, with intermediate formation of a kind of tin, with the compound of the formula (lll) Cl ,,,, ¢: ,,, I + Oi "N" O "(j), 20 to give the compound of the formula (M
F 7 ==
, = r'_ NH, H2N "i ¢ jo_ d (lV),
this is then reduced in an inert solvent with an appropriate reducing agent to give the compound of the formula N) F
p i '> A ~ I
^ ^ lj ~ / "µ
"r H, N" D - ,,, NH, N)
this is then reacted in the presence of an appropriate base with or without solvent with methylester of chloroformic acid to form the
5 compound of the formula (I-A)
Á "¶Z> ,, H2N" NH
° = (The H3C "(I-A),
or [B] the compound of the formula (jj) is reacted in an inert solvent with copper cyanide to give the compound of the formula (Vl)
F) == lN ~ N, ~ "" 1 "" '"(Vl), this is then converted, under acidic conditions, to the compound of the formula (VIl), F ~" |,' IjN, k = NH ^ at 0 H, N x H, CCO2H (V11), * this is subsequently reacted in an inert solvent in the presence of an appropriate base with the compound of the formula (V111) "Y" N "/ NC (V '") to give the compound of the formula (lX) Fy, jcy :: N D - ,,, H'N "N <, N / == J (lX), and this is then reduced in an inert solvent in the presence -
an appropriate reducing agent to give compound N), and this is then reacted according to process [A] to form the compound (IA), or 5 [C] the compound of the formula ( IA) is reacted in an inert solvent in the presence of an appropriate base with a compound of the formula (X) R '^ "X' (X), in which 10 R'a represents (C1-C4) -a | qui | a , where (C1-C4) -a | kila can be substituted by one or two substituents, independent of each other, selected from the group of fluorine and triflu- ^ «ormethyl,
W and j5 X1 represents a leaving group such as, for example, halogen, in particular bromine or iodine, trichloromethanesulfonate, methylate or 'tosylate, to form a compound of the formula (IB) ÁJ ", ¢ 7t _ NH,' "O = i, k-R '^, 0 H3C (IB) in which R1a has the meaning given above, 20 and the compounds resulting from formulas (IA) and (IB) are, if appropriate, converted (j) with solvents and / or (ii) corresponding acids or bases
corresponding, in their solvates, salts and / or solvates of the salts.
[5]
A compound of formula (I) as defined in any of claims 1 to 3, for the treatment and / or prophylaxis of diseases.
[6]
6. A compound of the formula (I) as defined in any of the 5 claims 1 to 3, for use in a method for the treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disorders, renal failure, thromboembolic disorders, fibrotic diseases and arteriosclerosis.
[7]
7. Use of a compound of formula (I) as defined in any of claims 1 to 3, for the preparation of a medication for the treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vasculature disorders. .. res, renal failure, tromembolic disorders, fibrotic disorders and ar- "teriosclerosis. 15
[8]
8. Medicament comprising a compound of formula (I) as defined in any of claims 1 to 3, in combination. with an inert, non-toxic, pharmaceutically appropriate excipient.
[9]
9. Medicament comprising a compound of the formula (I) as defined in any of claims 1 to 3, in combination with another active compound selected from the group consisting of organic nitrates, NO donors, cGMP-PDE inhibitors , agents containing antithrombotic activity, agents that lower blood pressure, and agents that alter lipid metabolism.
[10]
Medicament according to claim 7 or 8, for the treatment and / or prophylaxis of heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disorders, renal failure, thromboembolic diseases, fibrotic diseases and arteriosclerosis.
[11]
11. Method for the treatment and / or prophylaxis of heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, 30 vascular disorders, renal failure, thromboembolic disorders, fibrotic disorders and arteriosclerosis in humans and animals by administration of a effective amount of at least one compound of formula (I) as defined in any of claims 1 to 3, or of a medicament as defined in any of claims 8 to 10.
r * ©

类似技术:

---

公开号 | 公开日 | 专利标题

---

US10736896B2|2020-08-11|Substituted 5-fluoro-1H-pyrazolopyridines and their use

---

US9266871B2|2016-02-23|Trifluoromethyl-substituted fused pyrimidines and their use

---

US9309239B2|2016-04-12|Substituted 6-fluoro-1H-pyrazolo[4,3-b]pyridines and use thereof

---

ES2616042T3|2017-06-09|Benzyl substituted pyrazolopyridines and their use

---

US8765769B2|2014-07-01|Ring-fused 4-aminopyrimidines and use thereof as stimulators of soluable guanylate cyclases

---

US9605008B2|2017-03-28|Benzyl-1H-pyrazolo[3,4-b]pyridines and use thereof

---

US9771360B2|2017-09-26|Cyano-substituted imidazo[1,2-A]pyridinecarboxamides and their use

---

US9150580B2|2015-10-06|Substituted imidazopyridines and the use thereof

---

CA2910144A1|2014-05-08|Carboxy-substituted imidazo[1,2-a]pyridinecarboxamides and their use as soluble guanylate cyclase stimulants

---

US20170057954A1|2017-03-02|Substituted imidazo[1,2-a]pyridinecarboxamides and their use

---

CA2947374A1|2015-11-05|Enantiomers of the n-|-8-[|oxy]-2-methylimidazo[1,2-a]pyridine-3-carboxamide, as well as of the di- and trifluoro derivatives for the treatment of cardiovascular diseases

同族专利:

---

公开号 | 公开日

---

NO2021032I1|2021-09-06|

---

AU2011257335A1|2012-12-20|

---

AU2011257335B2|2015-12-03|

---

CY1117372T1|2017-04-26|

---

UY33396A|2011-12-30|

---

CL2012003226A1|2013-07-26|

---

TW201210592A|2012-03-16|

---

MY164356A|2017-12-15|

---

US20130237551A1|2013-09-12|

---

US10736896B2|2020-08-11|

---

EP2576547A1|2013-04-10|

---

TWI516263B|2016-01-11|

---

EP2576547B1|2016-01-27|

---

ES2567795T3|2016-04-26|

---

US20160129004A1|2016-05-12|

---

JP5896991B2|2016-03-30|

---

AR081628A1|2012-10-10|

---

CA2800697A1|2011-12-01|

---

EA023631B1|2016-06-30|

---

US20150080414A1|2015-03-19|

---

CN102939289A|2013-02-20|

---

EA201291336A1|2013-04-30|

---

CU24086B1|2015-03-30|

---

MA34248B1|2013-05-02|

---

KR101862420B1|2018-07-04|

---

HUS2100032I1|2021-09-28|

---

JO3199B1|2018-03-08|

---

RS54704B1|2016-08-31|

---

CR20120596A|2013-04-22|

---

DK2576547T3|2016-04-25|

---

KR20130116000A|2013-10-22|

---

GT201200313A|2014-01-31|

---

ME02393B|2016-09-20|

---

EA023631B9|2017-04-28|

---

CA2800697C|2018-08-07|

---

US8420656B2|2013-04-16|

---

CN102939289B|2016-01-20|

---

HRP20160370T1|2016-05-06|

---

US20180263981A1|2018-09-20|

---

CO6640226A2|2013-03-22|

---

TN2012000549A1|2014-04-01|

---

DE102010021637A1|2011-12-01|

---

LTPA2021518I1|2021-09-10|

---

JP2013530150A|2013-07-25|

---

ECSP12012310A|2012-12-28|

---

SG185460A1|2012-12-28|

---

PL2576547T3|2016-07-29|

---

IL249669A|2020-05-31|

---

HUE026912T2|2016-07-28|

---

US9266885B2|2016-02-23|

---

MX2012013324A|2012-12-05|

---

IL223050A|2017-01-31|

---

WO2011147809A1|2011-12-01|

---

SI2576547T1|2016-05-31|

---

CU20120161A7|2013-02-26|

---

PE20130402A1|2013-04-13|

---

NZ603800A|2014-10-31|

---

US9993476B2|2018-06-12|

---

IL223050D0|2013-02-03|

---

US8921377B2|2014-12-30|

---

US20170273977A1|2017-09-28|

---

UA109660C2|2015-09-25|

---

HK1182112A1|2013-11-22|

---

US20120022084A1|2012-01-26|

---

DOP2012000299A|2013-03-31|

---

US20200397785A1|2020-12-24|

---

IL249669D0|2017-02-28|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

JPH01198481A|1988-02-01|1989-08-10|Canon Inc|Formation of deposited film by microwave plasma cvd|

---

GB9013750D0|1990-06-20|1990-08-08|Pfizer Ltd|Therapeutic agents|

---

EP0463754A1|1990-06-25|1992-01-02|Rohm And Haas Company|Stabilization of glutarimide polymers|

---

DK181190D0|1990-07-30|1990-07-30|Lundbeck & Co As H|3-ARYL-INDOL OR 3-ARYL-INDAZOL DERIVATIVES|

---

GB9301192D0|1993-06-09|1993-06-09|Trott Francis W|Flower shaped mechanised table|

---

GB9314412D0|1993-07-13|1993-08-25|Rhone Poulenc Agriculture|New compositions of matter|

---

GB9401090D0|1994-01-21|1994-03-16|Glaxo Lab Sa|Chemical compounds|

---

TR199901174T2|1996-10-14|1999-08-23|Bayer Aktiengesellschaft|New heterocyclylmethyl-substituted pyrazole derivatives.|

---

DE19642255A1|1996-10-14|1998-04-16|Bayer Ag|Use of 1-benzyl-3- fused pyrazole derivatives|

---

US6008243A|1996-10-24|1999-12-28|Agouron Pharmaceuticals, Inc.|Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use|

---

US6451805B1|1997-11-14|2002-09-17|Bayer Aktiengesellschaft|Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases|

---

FR2757157B1|1996-12-13|1999-12-31|Sanofi Sa|INDOLIN-2-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

CU23063A3|1997-11-12|2005-07-19|Bayer Ag|IMIDAZOTRIAZINONES 2-PHENYL REPLACED AS PHOSPHODESTERASE INHIBITORS|

---

DE19834045A1|1998-07-29|2000-02-03|Bayer Ag| -1- -1H-pyrazolo [3,4-b] pyridine|

---

DE19834047A1|1998-07-29|2000-02-03|Bayer Ag|Substituted pyrazole derivatives|

---

DE19834044A1|1998-07-29|2000-02-03|Bayer Ag|New substituted pyrazole derivatives|

---

DE19846514A1|1998-10-09|2000-04-20|Bayer Ag|New arylmethyl and heterocyclylmethyl substituted heteroaryl-indazole derivatives useful in treatment of cardiovascular, ischemic and urogenital disorders|

---

GB0002666D0|2000-02-04|2000-03-29|Univ London|Blockade of voltage dependent sodium channels|

---

DE10057751A1|2000-11-22|2002-05-23|Bayer Ag|New carbamate-substituted pyrazolo pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation|

---

ES2231581T3|2000-11-22|2005-05-16|Bayer Healthcare Ag|NEW DERIVATIVES OF PIRAZOLOPIRIDINE REPLACED WITH LACTAMA.|

---

AR031176A1|2000-11-22|2003-09-10|Bayer Ag|NEW DERIVATIVES OF PIRAZOLPIRIDINA SUBSTITUTED WITH PIRIDINE|

---

DE10057754A1|2000-11-22|2002-05-23|Bayer Ag|New cyclic sulfonamido-substituted pyrazolo pyridine derivatives, are soluble guanylate cyclase stimulants useful e.g. for treating cardiovascular or central nervous system diseases, sexual dysfunction or inflammation|

---

NZ526871A|2001-01-25|2006-01-27|Squibb Bristol Myers Co|Pharmaceutical dosage forms of epothilones for oral administration|

---

DE10122894A1|2001-05-11|2002-11-14|Bayer Ag|New pyrazolopyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases|

---

DE10132416A1|2001-07-04|2003-01-16|Bayer Ag|New morpholine-bridged pyrazolopyridine derivatives|

---

US7666867B2|2001-10-26|2010-02-23|University Of Connecticut|Heteroindanes: a new class of potent cannabimimetic ligands|

---

US7790905B2|2002-02-15|2010-09-07|Mcneil-Ppc, Inc.|Pharmaceutical propylene glycol solvate compositions|

---

WO2003076408A2|2002-03-08|2003-09-18|Abbott Laboratories|Indazole derivatives that are activators of soluble guanylate cyclase|

---

GR1004350B|2002-03-29|2003-09-26|Δημητριος Κωνσταντινου Πενταφραγκας|Inhaler for dry powder|

---

DE10220570A1|2002-05-08|2003-11-20|Bayer Ag|Carbamate-substituted pyrazolopyridines|

---

DE10222550A1|2002-05-17|2003-11-27|Bayer Ag|New 1-benzyl-3--pyrazolo--pyridine derivatives are soluble guanylate cyclase stimulants, useful e.g. for treating cardiovascular or thromboembolic diseases or sexual dysfunction|

---

DE10232571A1|2002-07-18|2004-02-05|Bayer Ag|4-amino substituted pyrimidine derivatives|

---

DE10232572A1|2002-07-18|2004-02-05|Bayer Ag|New 2,5-disubstituted pyrimidine derivatives|

---

DE10242941A1|2002-09-16|2004-03-18|Bayer Ag|New 2--pyridinyl)-5-pyridinyl-4-pyrimidinylamine derivative, is a soluble guanylate cyclase stimulant useful e.g. for treating cardiovascular diseases, hypertension or ischemia|

---

DE10244810A1|2002-09-26|2004-04-08|Bayer Ag|New morpholine-bridged indazole derivatives|

---

EP2161258A3|2002-11-20|2010-04-07|Japan Tabacco Inc.|4-oxoquinoline compound and use thereof as hiv integrase inhibitor|

---

JP4765623B2|2003-05-09|2011-09-07|旭硝子株式会社|Process for producing 2-chloro-5-fluoro-3-substituted pyridine or a salt thereof|

---

KR20060110741A|2003-06-30|2006-10-25|히프 바이오 인크|Compounds, compositions and methods|

---

TWI258478B|2003-10-31|2006-07-21|Arena Pharm Inc|Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof|

---

CN100355732C|2003-11-03|2007-12-19|上海药明康德新药开发有限公司|Preparation of 2-Cl-5-F-nicotinate and nicotonic acid|

---

DE10351903A1|2003-11-06|2005-06-09|Bayer Healthcare Ag|New combination|

---

GB0403819D0|2004-02-20|2004-03-24|Merck Sharp & Dohme|New compounds|

---

US7514463B2|2004-08-20|2009-04-07|University Of Kansas|Lonidamine analogues and their use in male contraception and cancer treatment|

---

WO2006037491A1|2004-10-05|2006-04-13|Bayer Healthcare Ag|A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction|

---

KR20080030669A|2005-07-18|2008-04-04|바이엘 헬스케어 아게|Novel use of activators and stimulators of soluble guanylate cyclase for the prevention or treatment of renal disorders|

---

DE102006021733A1|2006-05-09|2007-11-22|Bayer Healthcare Ag|3-tetrazolylindazoles and 3-tetrazolylpyrazolopyridines and their use|

---

DE102006043443A1|2006-09-15|2008-03-27|Bayer Healthcare Ag|Novel aza-bicyclic compounds and their use|

---

CA2691888A1|2007-06-25|2008-12-31|Boehringer Ingelheim International Gmbh|New chemical compounds|

---

WO2009018415A1|2007-07-31|2009-02-05|Vertex Pharmaceuticals Incorporated|Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof|

---

WO2009145814A2|2008-03-10|2009-12-03|Vertex Pharmaceuticals Incorporated|Pyrimidines and pyridines useful as inhibitors of protein kinases|

---

DE102008063992A1|2008-12-19|2010-09-02|Lerner, Zinoviy, Dipl.-Ing.|New aliphatic substituted pyrazolopyridines and their use|

---

DE102009004245A1|2009-01-09|2010-07-15|Bayer Schering Pharma Aktiengesellschaft|Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use|

---

AR077898A1|2009-08-26|2011-09-28|Nycomed Gmbh|METHYLPIRROLOPIRIMIDINCARBOXAMIDS|

---

UY33041A|2009-11-27|2011-06-30|Bayer Schering Pharma Aktienegesellschaft|PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE|

---

SI3415515T1|2009-11-27|2020-03-31|Adverio Pharma Gmbh|Method for the preparation of methyl--1h-pyrazolopyridin-3-yl)pyrimidin-5-yl)methylcarbamate|

---

UY33040A|2009-11-27|2011-06-30|Bayer Schering Pahrma Akitengesellschaft|NEW FORMS POLYMORPHES OF {4,6DIAMINO-2- [1- (2-FLUOROBENCIL-1H-PIRAZOL [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} METHYL CARBAMATE|

---

WO2011115804A1|2010-03-17|2011-09-22|Ironwood Pharmaceuticals, Inc.|Sgc stimulators|

---

DE102010021637A1|2010-05-26|2011-12-01|Bayer Schering Pharma Aktiengesellschaft|Substituted 5-fluoro-1H-pyrazolopyridines and their use|

---

EP2576548B1|2010-05-26|2015-06-24|Adverio Pharma GmbH|THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS |

---

KR101499308B1|2010-05-27|2015-03-05|머크 샤프 앤드 돔 코포레이션|Soluble guanylate cyclase activators|

---

MX2013000198A|2010-07-09|2013-01-28|Bayer Ip Gmbh|Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases.|

---

DE102010040233A1|2010-09-03|2012-03-08|Bayer Schering Pharma Aktiengesellschaft|Bicyclic aza heterocycles and their use|

---

DE102010040234A1|2010-09-03|2012-03-08|Bayer Schering Pharma Aktiengesellschaft|Process for the preparation of 5-fluoro-1H-pyrazolo [3,4-b] pyridine-3-carbonitrile|

---

DE102010043380A1|2010-11-04|2012-05-10|Bayer Schering Pharma Aktiengesellschaft|Benzyl-substituted carbamates and their use|

---

DE102010043379A1|2010-11-04|2012-05-10|Bayer Schering Pharma Aktiengesellschaft|Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use|

---

CA2835220A1|2011-05-31|2012-12-06|Theravance, Inc.|Neprilysin inhibitors|

---

US8859569B2|2011-09-02|2014-10-14|Bayer Pharma Aktiengesellschaft|Substituted annellated pyrimidines and use thereof|

---

CR20210072A|2011-11-25|2021-03-22|Adverio Pharma Gmbh|Method for producing substituted 5-fluoro-1h-pyrazolopyridines|

---

DE102012200352A1|2012-01-11|2013-07-11|Bayer Intellectual Property Gmbh|Substituted, fused imidazoles and pyrazoles and their use|DE102008063992A1|2008-12-19|2010-09-02|Lerner, Zinoviy, Dipl.-Ing.|New aliphatic substituted pyrazolopyridines and their use|

---

SI3415515T1|2009-11-27|2020-03-31|Adverio Pharma Gmbh|Method for the preparation of methyl--1h-pyrazolopyridin-3-yl)pyrimidin-5-yl)methylcarbamate|

---

WO2011119518A1|2010-03-25|2011-09-29|Merck Sharp & Dohme Corp.|Soluble guanylate cyclase activators|

---

DE102010021637A1|2010-05-26|2011-12-01|Bayer Schering Pharma Aktiengesellschaft|Substituted 5-fluoro-1H-pyrazolopyridines and their use|

---

KR101499308B1|2010-05-27|2015-03-05|머크 샤프 앤드 돔 코포레이션|Soluble guanylate cyclase activators|

---

MX2013000198A|2010-07-09|2013-01-28|Bayer Ip Gmbh|Ring-fused pyrimidines and triazines and use thereof for the treatment and/or prophylaxis of cardiovascular diseases.|

---

WO2012058132A1|2010-10-28|2012-05-03|Merck Sharp & Dohme Corp.|Soluble guanylate cyclase activators|

---

DE102010043380A1|2010-11-04|2012-05-10|Bayer Schering Pharma Aktiengesellschaft|Benzyl-substituted carbamates and their use|

---

DE102010043379A1|2010-11-04|2012-05-10|Bayer Schering Pharma Aktiengesellschaft|Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use|

---

WO2012143510A1|2011-04-21|2012-10-26|Bayer Intellectual Property Gmbh|Fluoroalkyl-substituted pyrazolopyridines and use thereof|

---

EP2594270A3|2011-11-18|2013-07-31|BIP Patents|The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis |

---

CR20210072A|2011-11-25|2021-03-22|Adverio Pharma Gmbh|Method for producing substituted 5-fluoro-1h-pyrazolopyridines|

---

CN102491974B|2011-12-12|2013-08-07|南京药石药物研发有限公司|Method for synthesizing 1--1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride|

---

DE102012200352A1|2012-01-11|2013-07-11|Bayer Intellectual Property Gmbh|Substituted, fused imidazoles and pyrazoles and their use|

---

DE102012200360A1|2012-01-11|2013-07-11|Bayer Intellectual Property Gmbh|Substituted triazines and their use|

---

DE102012200349A1|2012-01-11|2013-07-11|Bayer Intellectual Property Gmbh|Substituted fused pyrimidines and triazines and their use|

---

CN104395313B|2012-03-06|2017-03-08|拜耳知识产权有限责任公司|Azabicyclo replacing and application thereof|

---

WO2013144191A1|2012-03-29|2013-10-03|Bayer Intellectual Property Gmbh|Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases|

---

CN104703964B|2012-07-20|2017-04-12|拜耳制药股份公司|Substituted aminoindane- and aminotetralincarboxylic acids and use thereof|

---

CN104822661B|2012-07-20|2017-05-31|拜耳药业股份公司|Carboxylic acid of 5 amino tetrahydroquinoline 2 and application thereof|

---

KR102093608B1|2012-11-30|2020-03-26|아스테라스 세이야쿠 가부시키가이샤|Imidazopyridine compound|

---

CN105102457A|2013-02-21|2015-11-25|阿德弗里奥药品有限责任公司|Forms of methyl {4, 6-diamino-2-[1--1h-pyrazolo[3, 4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate|

---

EP2961755B1|2013-03-01|2017-10-18|Bayer Pharma Aktiengesellschaft|Trifluoromethyl-substituted ring-fused pyrimidines and use thereof|

---

CA2916103A1|2013-06-21|2014-12-24|Bayer Pharma Aktiengesellschaft|Diaminoheteroaryl substituted pyrazoles|

---

CN105745215A|2013-07-10|2016-07-06|拜耳制药股份公司|Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof|

---

EP3024455A1|2013-07-25|2016-06-01|Bayer Pharma Aktiengesellschaft|Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis|

---

UY35735A|2013-09-16|2015-04-30|Bayer Pharma AG|DISTRICTED TRIFLUOROMETILPIRIMIDINONES AND ITS USE|

---

KR20160065957A|2013-10-07|2016-06-09|바이엘 파마 악티엔게젤샤프트|Cyclic thienouracil-carboxamides and use thereof|

---

WO2015088885A1|2013-12-11|2015-06-18|Merck Sharp & Dohme Corp.|Soluble guanylate cyclase activators|

---

EP3079700B1|2013-12-11|2020-11-25|Merck Sharp & Dohme Corp.|Soluble guanylate cyclase activators|

---

WO2015106268A1|2014-01-13|2015-07-16|Ironwood Pharmaceuticals, Inc.|USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS|

---

WO2015150362A2|2014-04-03|2015-10-08|Bayer Pharma Aktiengesellschaft|Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof|

---

CA2944614A1|2014-04-03|2015-10-08|Bayer Pharma Aktiengesellschaft|2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases|

---

US20170022171A1|2014-04-03|2017-01-26|Bayer Pharma Aktiengesellschaft|2,5-disubstituted cyclopentanecarboxylic acids and their use|

---

EP3152214B1|2014-06-04|2020-01-29|Merck Sharp & Dohme Corp.|Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators|

---

WO2016037954A1|2014-09-09|2016-03-17|Bayer Pharma Aktiengesellschaft|Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents|

---

US10138236B2|2014-09-24|2018-11-27|Bayer Pharma Aktiengesellschaft|Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives|

---

CN107074783B|2014-11-03|2020-06-05|拜耳制药股份公司|Hydroxyalkyl substituted phenyl triazole derivatives and uses thereof|

---

TW201625635A|2014-11-21|2016-07-16|默沙東藥廠|Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators|

---

WO2016113205A1|2015-01-13|2016-07-21|Bayer Pharma Aktiengesellschaft|Substituted pentafluoroethyl pyrimidinones and use thereof|

---

UY36586A|2015-03-26|2016-10-31|Bayer Pharma AG|HETEROCICLILMETILTIENOURACILOS AND USE OF THE SAME|

---

JP6748113B2|2015-05-06|2020-08-26|バイエル・ファルマ・アクティエンゲゼルシャフト|Use of sGC stimulants, sGC activators alone or in combination with PDE5 inhibitors for treating digital ulcersassociated with systemic sclerosis |

---

WO2016191334A1|2015-05-27|2016-12-01|Merck Sharp & Dohme Corp.|Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators|

---

EP3310782B1|2015-05-28|2021-12-01|Merck Sharp & Dohme Corp.|Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators|

---

SI3325013T1|2015-07-23|2020-11-30|Bayer Pharma Aktiengesellschaft|Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof|

---

CN108699084A|2015-12-10|2018-10-23|拜耳制药股份公司|Replace perhydro Bi Kabing &#91;3,4-c&#93;Azole derivatives and application thereof|

---

JP2018536693A|2015-12-10|2018-12-13|バイエル・ファルマ・アクティエンゲゼルシャフト|2-Phenyl-3-imidazo [1,2-a] pyridine derivatives as blockers of TASK-1 and TASK-2 channels for treating sleep-related breathing disorders|

---

JP2019502686A|2015-12-14|2019-01-31|アイアンウッド ファーマシューティカルズ インコーポレイテッド|Use of sGC stimulators to treat gastrointestinal sphincter dysfunction|

---

CN105461715B|2015-12-15|2017-03-29|郑州大明药物科技有限公司|A kind of synthetic method of the western croak intermediate of Leo|

---

WO2017107052A1|2015-12-22|2017-06-29|Merck Sharp & Dohme Corp.|Soluble guanylate cyclase stimulators|

---

WO2017121692A1|2016-01-15|2017-07-20|Bayer Pharma Aktiengesellschaft|Substituted sulfamides and use of same|

---

WO2017153235A1|2016-03-09|2017-09-14|Bayer Pharma Aktiengesellschaft|Substituted n-cyclo-3-aryl-1-naphthamides and use thereof|

---

WO2017153234A1|2016-03-09|2017-09-14|Bayer Pharma Aktiengesellschaft|Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof|

---

WO2017153231A1|2016-03-09|2017-09-14|Bayer Pharma Aktiengesellschaft|Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof|

---

WO2017191105A1|2016-05-03|2017-11-09|Bayer Pharma Aktiengesellschaft|Amide-substituted aryltriazole derivatives and uses thereof|

---

WO2017191117A1|2016-05-03|2017-11-09|Bayer Pharma Aktiengesellschaft|V1a receptor antagonists for use in the treatment of renal diseases|

---

WO2017191107A1|2016-05-03|2017-11-09|Bayer Pharma Aktiengesellschaft|Amide-substituted phenyltriazole derivatives and uses thereof|

---

US10800746B2|2016-05-03|2020-10-13|Bayer Pharma Aktiengesellschaft|Oxoalkyl-substituted phenyltriazole derivatives and uses thereof|

---

EP3452469A1|2016-05-03|2019-03-13|Bayer Pharma Aktiengesellschaft|Fluoroalkyl-substituted aryltriazole derivatives and uses thereof|

---

EP3452472A1|2016-05-03|2019-03-13|Bayer Aktiengesellschaft|Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof|

---

US9988367B2|2016-05-03|2018-06-05|Bayer Pharma Aktiengesellschaft|Amide-substituted pyridinyltriazole derivatives and uses thereof|

---

KR20190003954A|2016-05-09|2019-01-10|바이엘 악티엔게젤샤프트|Tetrahydropyrrolo [4,3-a] pyridin-3-one and 2,5,6,7-tetrahydro-3H- Pyrrolo [2,1-c] [1,2,4] triazol-3-one, and uses thereof|

---

WO2017197555A1|2016-05-16|2017-11-23|Merck Sharp & Dohme Corp.|Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators|

---

WO2017200857A1|2016-05-18|2017-11-23|Merck Sharp & Dohme Corp.|Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders|

---

CN109689654A|2016-07-11|2019-04-26|拜耳医药股份有限公司|1- pyridyl group-naphthyridines -3- benzamide type and application thereof that 7- replaces|

---

SG11201900460RA|2016-07-20|2019-02-27|Bayer Ag|Substituted diazahetero-bicyclic compounds and their use|

---

WO2018041771A1|2016-09-02|2018-03-08|Bayer Pharma Aktiengesellschaft|methyl-substituted thienouraciles and use thereof|

---

CN109689656A|2016-09-14|2019-04-26|拜耳股份公司|The 1- aryl benzodiazine -3- carboxylic acid amides and application thereof that 7- replaces|

---

EP3296298A1|2016-09-14|2018-03-21|Bayer Pharma Aktiengesellschaft|7-substituted 1-aryl-naphthyridin-3-carboxamides and their use|

---

SG11201902588PA|2016-09-23|2019-05-30|Bayer Ag|N3-Cyclically Substituted Thienouracils And Use Thereof|

---

EP3525779A1|2016-10-11|2019-08-21|Bayer Pharma Aktiengesellschaft|Combination containing sgc stimulators and mineralocorticoid receptor antagonists|

---

TN2019000114A1|2016-10-14|2020-10-05|Bayer Ag|Substituted 6-pyrimidin-4-amine derivatives and uses thereof|

---

WO2018073144A1|2016-10-20|2018-04-26|Bayer Pharma Aktiengesellschaft|Hydroxyalkyl-substituted triazole derivatives and uses thereof|

---

EP3554488A2|2016-12-13|2019-10-23|Cyclerion Therapeutics, Inc.|Use of sgc stimulators for the treatment of esophageal motility disorders|

---

EP3338803A1|2016-12-21|2018-06-27|Bayer Pharma Aktiengesellschaft|Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders|

---

CR20190300A|2016-12-21|2019-09-23|Bayer Pharma AG|Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy|

---

EP3338764A1|2016-12-21|2018-06-27|Bayer Pharma Aktiengesellschaft|Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders|

---

JP2020502215A|2016-12-21|2020-01-23|バイエル・ファルマ・アクティエンゲゼルシャフト|Pharmaceutical dosage forms comprising TASK-1 and TASK-3 channel inhibitors and their use in respiratory disorder therapy|

---

WO2018153899A1|2017-02-22|2018-08-30|Bayer Pharma Aktiengesellschaft|Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclasestimulators and/or activators|

---

TW201900616A|2017-04-10|2019-01-01|德商拜耳廠股份有限公司|Substituted N-arylethyl-2-aminoquinoline-4-carboxamide and use thereof|

---

WO2018189011A1|2017-04-10|2018-10-18|Bayer Aktiengesellschaft|Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof|

---

EP3609883A4|2017-04-11|2020-12-09|Sunshine Lake Pharma Co., Ltd.|Fluorine-substituted indazole compounds and uses thereof|

---

CN108690016A|2017-04-11|2018-10-23|广东东阳光药业有限公司|Pyrazolo-pyridines and application thereof|

---

MX2019014983A|2017-06-14|2020-02-24|Bayer Ag|Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders.|

---

WO2018227427A1|2017-06-14|2018-12-20|Bayer Aktiengesellschaft|Substituted bridged diazepane derivatives and use thereof|

---

MA50438A|2017-10-24|2020-09-02|Bayer Ag|SUBSTITUTED TRIAZOLE DERIVATIVES AND USES|

---

WO2019081291A1|2017-10-24|2019-05-02|Bayer Aktiengesellschaft|Prodrugs of substituted triazole derivatives and uses thereof|

---

WO2019081299A1|2017-10-24|2019-05-02|Bayer Pharma Aktiengesellschaft|Amine substituted triazole derivatives and uses thereof|

---

WO2019081307A1|2017-10-24|2019-05-02|Bayer Aktiengesellschaft|Substituted triazole derivatives and uses thereof|

---

CA3084421A1|2017-10-24|2019-05-02|Bayer Pharma Aktiengesellschaft|Substituted triazole derivatives and uses thereof|

---

EP3700903A1|2017-10-24|2020-09-02|Bayer Aktiengesellschaft|Substituted imidazopyridine amides and use thereof|

---

EP3700899A1|2017-10-24|2020-09-02|Bayer Pharma Aktiengesellschaft|Substituted triazole derivatives and uses thereof|

---

EP3700897A1|2017-10-24|2020-09-02|Bayer Pharma Aktiengesellschaft|Substituted triazole derivatives and uses thereof|

---

WO2019091847A1|2017-11-07|2019-05-16|Bayer Aktiengesellschaft|Substituted 2,4-dihydro-3h-1,2,4-triazol-3-ones and use of same|

---

KR20200094762A|2017-12-01|2020-08-07|바이엘 파마 악티엔게젤샤프트|-3--2--4,4,4-trifluoro-3-methylbutanoyl for use as a pharmaceutical ingredient ]Amino}phenyl)-3-cyclo-propylpropanoic acid and method for preparing crystalline form thereof|

---

EP3553081A1|2018-04-12|2019-10-16|Bayer Aktiengesellschaft|Atrial natriuretic peptide engrafted antibodies|

---

EP3553079A1|2018-04-12|2019-10-16|Bayer Aktiengesellschaft|C-type natriuretic peptide engrafted antibodies|

---

EP3553082A1|2018-04-12|2019-10-16|Bayer Aktiengesellschaft|Brain natriuretic peptide engrafted antibodies|

---

EP3787610A1|2018-04-30|2021-03-10|Bayer Aktiengesellschaft|The use of sgc activators and sgc stimulators for the treatment of cognitive impairment|

---

EP3566704A1|2018-05-11|2019-11-13|Bayer Aktiengesellschaft|The use ofnon-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases|

---

CA3100096A1|2018-05-15|2019-11-21|Bayer Aktiengesellschaft|1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization|

---

BR112020021612A2|2018-05-17|2021-01-26|Bayer Aktiengesellschaft|substituted dihydropyrazole pyrazine carboxamide derivatives|

---

US20190371469A1|2018-05-30|2019-12-05|Adverio Pharma Gmbh|Method of Identifying a Subgroup of Patients Suffering from DcSSc which Benefits from a Treatment with sGC Stimulators and sGC Activators in a Higher Degree than a Control Group|

---

WO2020014504A1|2018-07-11|2020-01-16|Cyclerion Therapeutics, Inc.|USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS|

---

TW202019402A|2018-07-24|2020-06-01|德商拜耳廠股份有限公司|Orally administrable modified-release pharmaceutical dosage form|

---

US10905667B2|2018-07-24|2021-02-02|Bayer Pharma Aktiengesellschaft|Orally administrable modified-release pharmaceutical dosage form|

---

WO2020020790A1|2018-07-24|2020-01-30|Bayer Aktiengesellschaft|Pharmaceutical dosage form which can be administered orally and has modified release|

---

EP3886806A1|2018-11-27|2021-10-06|Bayer Aktiengesellschaft|Process for producing pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy|

---

TW202039488A|2018-12-17|2020-11-01|德商亞德維瑞醫藥有限公司|Methyl {4,6-diamino-2-[5-fluoro-1--1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate active compound product having improved properties, production and formulation thereof|

---

WO2020164008A1|2019-02-13|2020-08-20|Bayer Aktiengesellschaft|Process for the preparation of porous microparticles|

---

WO2020216669A1|2019-04-23|2020-10-29|Bayer Aktiengesellschaft|Phenyl-substituted imidazopyridine amides and use thereof|

---

CA3139209A1|2019-05-07|2020-11-12|Bayer Aktiengesellschaft|Masp inhibitory compounds and uses thereof|

---

WO2020245342A1|2019-06-07|2020-12-10|Bayer Aktiengesellschaft|The use of sgc activators for the treatment of ophthalmologic diseases|

---

TW202132292A|2019-11-06|2021-09-01|德商拜耳廠股份有限公司|Substituted heterocyclic carboxamides and their use|

---

WO2021094210A1|2019-11-12|2021-05-20|Bayer Aktiengesellschaft|Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists|

---

WO2021094208A1|2019-11-12|2021-05-20|Bayer Aktiengesellschaft|Substituted imidazo pyrimidine ep3 antagonists|

---

WO2021094209A1|2019-11-12|2021-05-20|Bayer Aktiengesellschaft|Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists|

---

EP3822268A1|2019-11-15|2021-05-19|Bayer Aktiengesellschaft|Substituted hydantoinamides as adamts7 antagonists|

---

EP3822265A1|2019-11-15|2021-05-19|Bayer AG|Substituted hydantoinamides as adamts7 antagonists|

---

WO2021156223A1|2020-02-03|2021-08-12|Adverio Pharma Gmbh|Nanoformulations of methyl {4,6-diamino-2-[5-fluoro-1--1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate|

---

WO2021167458A1|2020-02-21|2021-08-26|Universiteit Maastricht|Use of a soluble guanylate cyclasestimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme|

---

WO2021172982A1|2020-02-26|2021-09-02|Universiteit Maastricht|Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia|

---

WO2021195403A1|2020-03-26|2021-09-30|Cyclerion Therapeutics, Inc.|Deuterated sgc stimulators|

---

EP3925953A4|2020-06-16|2021-12-22|Adverio Pharma Gmbh|Process for preparing methyl {4,6-diamino-2-[5-fluoro-1--1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate|

法律状态:
2020-10-20| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2020-10-27| B25A| Requested transfer of rights approved|Owner name: ADVERIO PHARMA GMBH (DE) |

---

2020-10-27| B07D| Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]|Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |

---

2021-02-23| B07E| Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]|

---

2021-03-02| B25G| Requested change of headquarter approved|Owner name: ADVERIO PHARMA GMBH (DE) |

---

2021-03-09| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2021-05-18| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2021-09-08| B09B| Patent application refused [chapter 9.2 patent gazette]|

---

2021-11-16| B12B| Appeal against refusal [chapter 12.2 patent gazette]|

---

2021-11-23| B350| Update of information on the portal [chapter 15.35 patent gazette]|

优先权:

---

申请号 | 申请日 | 专利标题

---

DE102010021637A|DE102010021637A1|2010-05-26|2010-05-26|Substituted 5-fluoro-1H-pyrazolopyridines and their use|

---

DE102010021637.2|2010-05-26|

---

PCT/EP2011/058431|WO2011147809A1|2010-05-26|2011-05-24|Substituted 5-fluoro-1h-pyrazolopyridines and use thereof|

---